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11.INTRODUCTION
Periodontal diseases are recognized as the major public health problem throughout the
world. Daily oral hygiene plays a vital role in maintaining healthy teeth and gums.
Periodontal disease can do occur in all age groups, ethnicities, races, genders and
socioeconomic levels.
The term “Periodontal Disease” broadly defines several diseases associated
with the periodontium. Changes in the microflora, histopathological variations,
clinical symptoms, and the location of the inflammation help to further delineate
periodontal disease. Gingivitis, the moderate stage of the disease, caused by an
accumulation of supragingival plaque is characterized by swelling, light bleeding and
redness of marginal gingiva. Gingivitis is associated with a change in microflora,
shifting from a grampositive anaerobic flora to a more gram-negative flora.
Periodontitis a more severe stage of periodontal disease, results in the resorption of
the alveolar bone and detachment of the periodontal ligaments supporting the tooth.
Figure No.1.1: Comparision of Healthy Periodontum/Gums and Periodontal
Disease.
2One of the clinical features of the periodontal disease is the formation of periodontal
pocket, which is pathologically deepened sulcus. In normal sulcus, the gap between
the gingiva and the tooth is normally between 1 and 3 mm deep. However, during
periodontitis, the depth of pocket usually exceeds 5mm1.
Causes of Periodontal Diseases:
The main cause of periodontal disease is bacteria plaque, a sticky, colorless film that
constantly forms on teeth. However, factors like smoking/ tobacco use, genetics,
pregnancy and puberty, stress, medication, clenching or grinding teeth, diabetes and
poor nutrition also lead to periodontal diseases. Plaque (more plaque formation)
Gingival inflammation Pocket formation Periodontal pathogens grow only where
atmosphere and nutrient composition are strictly conductive to their requirements and
the disease once established, causes major changes in the periodontal
microenvironment. The gingival crevicular fluid (GCF) flow occurs at extremely low
levels in healthy gingival sulci but increases enormously to 3.5ml/day or more. The
most commonly grown anaerobic pathogenic bacteria are Actinobacillus
actinomycetencomitans, Bacteroides gingivalis, Bacteroides melaninogenicus sub
species intermedius, Porphyromonas gingivalis and Prevotella intermedia. Clinical
signs such as bluish red thickened marginal gingiva, bluish red vertical zone from the
gingival margin to the oral mucosa, gingival bleeding and localized pain are
suggestive of the presence of periodontal pockets 2, 3.
Overview of the Pathogenesis of Periodontal Disease:
The normal healthy gingiva is characterized by its pink color, its firm consistency and
free from histological evidence of inflammation, but this ideal condition is very rarely
seen in microscopic tissue sections. This is because most human gingival tissues are,
no matter how clinically healthy in appearance, slightly inflamed due to constant
3presence of microbial plaque. Even in healthy state, the gingiva has a leukocyte
infiltrate that is predominantly comprised of neutrophils or polymorphonuclear
leukocytes. These leukocytes rephagocytose whose primary purpose is to kill bacteria
in the gingival crevicular area or the gingival pocket. Neutrophils are recruited to the
periodontal pocket or the gingival crevice because of attracting molecules, released by
bacteria, called chemtactic peptides. Furthermore, as bacteria damage the epithelial
cells, they cause epithelial cells to release molecules termed cytokines that further
attract leukocytes to the crevice. The neutrophilscan phagocytose and digest bacteria
within crevice and therefore remove these bacteria from the pocket. If the neutrophil
becomes overloaded with bacteria, it degranulates or explodes. This causes tissue
damage from toxic enzymes that are released from the neutrophils. Therefore,
neutrophils can be viewed as being both helpful and potentially harmful. Depending
on the  individual, progression from gingivitis to periodontitis requires varying
amounts of time. But in normal situation, more than 6 months may be needed for the
lesion of gingivitis to change to periodontitis 4, 5, 6.
Microbiology of Periodontal Disease:
About 300 or  400 bacterial species are found in the  human subgingival plaque
samples. Of that number, possibly 10-20 species may play a role in the pathogenesis
of destructive periodontal disease. These bacterial species must be able to colonize in
order to survive and damage the periodontal tissues. To colonize subgingival sites,
microbes must be able to,
1) Attach to periodontal tissues
2) Multiply
3) Compete with other microbes in their habitat and
44) Defend themselves from host defense mechanisms.
The gingival sulcus area is a lush place for microbial growth, but in order to colonize
a subgingival site, a bacterial species must overcome a number of host-derived
obstacles. If a species successfully enters underlying connective tissue, it faces a
multitude of host immune cells including B and T lymphocytes, neutrophils,
macrophages and lymphocytes. To be successful, bacteria must have the ability to
evade all these host response mechanisms. The microbes involved in periodontal
disease are largely gram-negative anaerobic bacilli with some anaerobic cocci and a
large quantity of anaerobic spirochetes 4, 8, 9.
Histopathological Changes:
The major pathological features of periodontitis are the accumulation of an
inflammatory infiltrate in the tissue adjacent to the periodontal pocket, breakdown of
connective tissue fibers anchoring the root to gingival connective tissue and alveolar
bone, apical migration of the epithelial attachment or junctional epithelium, and
resorption of the marginal portion of the alveolar bone resulting in eventual tooth loss.
Page & Schroeder developed a system to categorize the clinical and histopathological
stages of periodontal disease and defined four histopathological stages of periodontal
inflammatory changes.
• Health – Pristine Condition
• Initial lesion – Clinically healthy
• Early lesion – Early gingivitis
• Established lesion – Chronic gingivitis
• Advanced lesion – Chronic periodontitis
5Following histopathological description by Kinane and Lindhe is based on model
Proposed by Page & Schroeder is summarized in table below 4,7,10
Table No.1.1: Histopathological Description
Clinical
condition
Histopathological condition
1. Pristine gingiva Histological perfection
2. Normal healthy
gingiva
Initial lesion
3. Early gingivitis Early lesion
4. Established
gingivitis
Established lesion with no bone loss nor apical
epithelial migration (Plasma cell density between 10%
and 30% of leukocyte infiltrate.
5. Periodontitis Established lesion with bone loss and apical epithelial
migration from the cement enamel junction (Plasma
cell density >50%).
The initial lesion appears within 4 days of plaque accumulation, characterized by an
acute inflammatory response. The major features consist of an increased flow of
crevicular fluid; inflammatory  infiltrate occupies 5% to 10% of the gingival
connective tissue below the epithelium and loss of collagen.
After approximately 7 days of plaque accumulation, an inflammatory infiltrate of
mononuclear leukocytes develops at the site of initial lesion as it progresses to the
early lesion. At this stage, the infiltrate occupies about 15% of the gingival connective
tissue, with collagen destruction in the infiltrated area reaching 60-70%. Clinically the
inflammatory changes are visible and present as edema and erythema.
After 2 to 3 weeks of plaque accumulation, the early lesion evolves into established
6lesion, characterized by further increase in the size, predominance of plasma cells and
lymphocytes at the periphery of lesion.
Features of advanced lesion include periodontal pocket formation, surface ulceration
and suppuration, destruction of alveolar bone and periodontal ligament, tooth
periodontitis is marked by the change in T-cell to B-cell predominance.
Mobility and drifting, and eventually tooth loss. The advanced lesion characterized by
the same feature present in the established gingival lesion.
TREATMENT APPROACHES
Conventional Periodontal therapy:
The purpose of periodontal treatment is to cure the inflamed tissue, reduce the number
of pathogenic bacteria and eliminate the depth of the diseased pockets and to stop
bone resorption. The conventional methods of pocket elimination are more or less
mechanical and are aimed at removal of supra and mechanical plaque and degenerated
and necrotic tissue lining the gingival wall of periodontal pockets through scaling,
root planning and curettage11.
The mechanical debridement alone often leaves behind significant number of
pathogens due to possible instrumentation or ability of microorganism to penetrate
into deeper tissues. Inaccessibility and recolonization of pathogens can occur after
scaling and root planning. With oral hygiene, a pathogenic subgingival microbial may
reestablish within 42 - 60 days after a single periodontal debridement session13. Some
deep periodontal pockets experience putative pathogen recolonization by 120 - 240
days despite multiple sessions of subgingival instrumentation and meticulous supra
gingival plaque control12.
7Antibiotic Therapy:
The use of antibiotics in the treatment of periodontal diseases helps to reduce or
eliminate bacteria that cannot be removed by scaling and root planning.
Chemotherapeutic agents can be administered systemically or locally. Tetracycline’s,
imidazole derivatives, fluoroquinolones etc., are the most favored antibiotics.
Antimicrobials used to treat dental infections can be divided into two main categories,
i.e., broad spectrum and narrow spectrum. Narrow-spectrum antimicrobials include
penicillin, amoxicillin, cephalexin, macrolides and tetracyclines. These drugs are
having a limited antimicrobial efficacy (Table1.2), as they are not effective against
aerobic and anaerobic beta lactamase producers, as well as other specific organisms14
Systemic  periodontal antimicrobial therapy is based on the premise that specific
microorganism cause destructive periodontal disease and that the antimicrobial agent
in the periodontal pocket can exceed the concentration necessary to kill the pathogens.
Systemic antibiotics can reach microorganisms at the  base of  deep periodontal
pockets and furcation areas via serum and may also affect organisms residing within
gingival epithelial and connective tissue. With systemic antibiotic therapy there is a
considerable variability in the therapeutic activity due to factors like poor absorption
in the gastrointestinal tract, first pass metabolism, systemic distribution, bacterial
sensitivity and resistance15.
Some studies also report poor results due to the fact that the active product does not
reach in adequate concentration at the site of action, as it is not retained locally for
sufficient period of several thousand folds before it reaches the site of action
8necessitating ingestion of large doses.
The increased toxic effects of these elevated dose levels make systemic administration
unacceptable due to low benefit to risk ratio. Repeated long term use of systemic
antibiotics is fraught with potential danger including resistant strains and super
infections17.
These draw backs can be markedly reduced if antimicrobial agent to be used locally.
Because of the smaller dosage used and topical chemotherapy is much safer than
systemic chemotherapy in avoiding the side effects of antibacterial agents16
Local Drug Delivery:
Local applications (as mouth rinse, gels, tooth paste etc,) control only supra gingival
microbial plaque or periodontal disease involving pocket formation and also requires
high initial concentrations and multiple applications in order to provide sustained
effectiveness18.
Local application of antibiotics has been achieved either by subgingival irrigation
or by incorporating the drug into different devices for insertion into periodontal
pockets. Many drugs like chlorhexidine, tetracycline are tried as mouth rinses in the
treatment of periodontal diseases. In-spite of its superior effects, chlorhexidine does
not reach the periodontal pocket when administered as mouth rinse. Subgingival
irrigation of antimicrobial involves local drug delivery but not controlled release.
Local drug delivery devices are of two types. In the first type, the drug delivery
system is designed to deliver agent locally in the periodontal pocket but without any
mechanism to retain therapeutic levels for a prolonged period of time. Such device
generally exhibits exponential increase and decrease in drug concentration at the
9site19.
Second type is the controlled release local drug delivery devices which may secure
antimicrobial effect for a prolonged period of time at the diseased site, than that can
be achieved by systemic or local topical applications and also by passes the systemic
complications20.
The controlled release delivery of antimicrobials directly into periodontal pocket has
received greatest interest and appears to hold some promise in periodontal therapy.
These delivery systems are produced by immobilizing antibiotic and antimicrobial
agents with a carrier substance to provide controlled local release.
Local antimicrobial therapy in periodontitis involve direct placement of antimicrobial
agents into subgingival sites minimizing the impact of the agents on non oral body
sites. Local antimicrobial agents may be personally applied as a part of home care oral
hygiene regimens and/or professionally applied as part of clinic based treatment
procedures. Local antimicrobial therapy in periodontitis may be further classified as
providing either non-sustained or sustained subgingival drug delivery. Non-sustained
subgingival drug delivery provides high pocket concentrations of the antimicrobial
agent over an extended time period within  periodontal pockets. Controlled drug
release can be  provided with subgingival irrigation of an agent intrinsically
substantive for both tooth surfaces or pocket placement of commercial antimicrobial
fibers, gel or films. The potential application of these new concepts to periodontology
and the treatment of periodontal infections was championed and developed into a
viable concept primarily by Dr. J. Max Goodson24.
10
Table 1.2:- Susceptibility of infective microorganisms to the major
antimicrobials.
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Aerobic
bacteria
Streptococc
-us Group A + + + + + + 0 A+ + +
Streptococc
-us spp + + + + + + 0 + + +
Staphylococ
-cus spp 0 + + + + + 0 A+ A+ +
Capnocytop
-haa spp + + + A+ A+ + 0 + + +
Eikenella
spp + 0 + 0 A+ 0 0 + + +
Anaerobic
bacteria
Peptostrepto
-coccus spp + + + + + + A+ A+ A+ +
Actinomyce
-s spp + + + + + + + A+ + +
Prevotella
spp + A+ + 0 0 + + A+ A+ A+
Porphyromo
-ns spp
A
+
A+ + 0 0 + + A+ 0 A+
Fusobaceriu
-m spp
A
+
A+ + 0 A+ + + A+ 0 A+
Bacteoride A
+
A+ + 0 0 + + A± 0 A±
A +: Higher activity towards organisms
+: Moderate activity
0: No activity
Cef/1 – first generation cephalosporins
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LOCAL ANTIMICROBIAL AGENT POCKET DELIVERY
Advantages of Local Controlled Release Devices:
• It is useful in controlling and monitoring the desired drug levels in the site.
• It allows local modification of tissue permeability inhibit protease activity or
decrease immunogenic response.
• It is a useful means of delivery of drug to the oral cavity that is not absorbed into
the gastro intestinal system (e.g. chlorhexidine).
• It bypasses hepatic first pass metabolism, therapy offering a greater bioavailability
and reduction in dosage21.
• The drug escapes the acidic environment of the stomach.
• Therapeutic serum concentrations of the drug can be achieved more rapidly
• Sustained release drugs offer a onetime application has an advantage over repeated
application.
Disadvantages:
• There is difficulty in placing therapeutic concentrations of antimicrobial agent into
deeper parts of periodontal pockets and frication lesions.
• Personal application of antimicrobial agent by patient’s lack of adequate manual
dexterity, limited understanding of periodontal anatomy and poor compliance and
performance with recommended procedures.
• The task of professionally applying local antimicrobial agent in periodontitis
patients with numerous advanced lesions distributed throughout their mouth is time
consuming and labor intensive.
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• Antimicrobial agents locally applied into periodontal pockets do not markedly
affect periodontal pathogens residing within adjacent gingival connective tissues
and on extra-pocket oral surfaces, which increases the risk of later reinfection and
disease recurrence in treated areas.
Success of any drug system designed to target periodontal infection depends upon its
ability to deliver the anti-microbial agent to the base of pocket at a bacteriostatic or
bactericidal concentration. It must also facilitate retention of medicament long enough
to ensure an efficacious result. Commonly used techniques22 to administer
antimicrobial with regard to attaining these criteria are compared in Table 1. 3.
TableNo.1.3: Comparison of Drug Delivery Systems for Management of
Periodontitis.
Mouth
Rinse
Subgingival
Irrigation
Systemic
delivery
Controlled
delivery
Reaches site of
disease and activity Poor Good Good Good
Adequate drug
concentration Good Good Fair Good
Adequate duration
of therapy Poor Poor Fair Good
Local antimicrobial therapy in periodontitis involves direct placement of an
antimicrobial agent(s) in to subgingival sites, minimizing the impact of the agent(s)
on non oral body sites.
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Types Of Local Antimicrobial Agent Therapy In Periodontal Diseases
Include.
1. Personally applied (in-patient home self care)
• Non-sustained subgingival drug delivery (home oral irrigation)
• Sustained subgingival drug delivery (Not developed to date)
2. Professionally applied (in dental office)
• Non sustained subgingival drug delivery (Professional pocket irrigation)
• Sustained subgingival drug delivery (Controlled release devices)
Controlled drug delivery systems are designed to deliver the drug slowly for
prolonged periods for sustaining drug action. These dosage forms are commonly
referred as sustained-release, controlled-release, timed-release and slow release.
These technologies assure therapeutic concentrations of the antimicrobial agents in
the subgingival area, at least for 3 days following  a single application. Most
controlled release  devices for periodontal application are  polymer based, with
diffusion of drugs across a rate controlling membrane.
CONTROLLED RELEASE LOCAL DELIVERY DEVICES
These devices employ the controlled release technologies to assure therapeutic
concentrations of  the antimicrobial in the  sub gingival area for at least 3 days
following a single application.
Different Types of Controlled Release Local Delivery Devices Fall Into
Following Groups
Reservoir devices (membrane diffusion systems)
This includes dialysis tubing 3-5 mm long, 0.2 mm wide containing a core of drug
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solution. This is left in the pocket for a week. Reservoir devices that lack rate control
include hollow fibers, gels and dialysis tubing. These systems tend to release
chemotherapeutic agents very  quickly and only marginally qualify as sustained
release devices. The problems associated with these devices are, irritation of the
pocket, premature loss from the pocket and rapid drug release23.
Monolithic devices
Bio absorbable, biodegradable materials can be left in situ. This eliminates the risk of
disturbing a site after therapy. The controlled release local delivery devices
(monolithic) are usually polymers (films/fibers) containing homogeneously dissolved
or dispersed drug.
In these devices, the drug is dispersed in a solid polymer matrix, Examples include
acrylic strips and ethylene vinyl acetate (EVA) fibers. Acrylic strips are typically 0-2
mm thick. Treatment is carried out over 2 - 4 weeks, with a replacement of new strips
inserted each week. Drug release occurs over a period of 10 - 14 days. Strips tend to
be lost from the pocket. This can be avoided by applying periodontal dressing. Other
monolithic devices include strips made of ethyl cellulose (EC), poly ethylene glycol
(PEG), Hydroxy propyl methyl cellulose (HPMC) and cross linked collagen films23.
The two basic types are:
1. Fixed monolithic devices: Where the polymer maintains its integrity as the drug is
lost.
2. Erodible monolithic devices: Which breaks up as the drug is released.
If the drug is present as dispersion, the release will be proportional to the square root
of time and if the drug is present only dissolved in the constant release rates, then
decay exponentially. It is possible to obtain more constant release rates by increasing
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the concentration of drug towards the center of the monolithic core to produce a
laminated device. The various polymers used for the monolithic device are ethylene
vinyl acetate co-polymer, ethyl cellulose, methyl methacrylate, poly ethylene-2
hydroxy ethyl methylacrylate, poly (ortho esters), atellocollagen etc.
The device should be designed for rapid insertion and to minimize the pain and
discomfort to the patient. The monolithic devices can be prepared conveniently by
using simple polymer fabrication techniques.
Melt fabrication Technique
Films can be produced by extrusion in to  thin film. Another process known as
calendaring, where the polymer is squeezed between heated rollers to form film23.
Solution casting
The polymer is dissolved in a suitable solvent to form a viscous solution, which is
then spread on flat non-adhesive surface and the solvent is allowed to evaporate. The
resultant film is peeled from the surface.
Polymerization In situ
A liquid polymer or pre polymerized inside a suitable mould. The release from
monolithic devices depends on diffusion of drug through matrix. By manipulating the
system, selecting the ideal polymer, adjusting the cross-linking, fillers, plasticizers
and by using co-polymers, release of some low molecular drug can be achieved.For
an antimicrobial agent to be successful the pathogen must be known, it must be
susceptible to the drug. It should not readily develop resistance for an adequate period
of time. Also the drug should have little or no side effects 24.
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MECHANISMS OF DRUG RELEASE
The release of drug from a localized drug delivery system can be achieved by the
following mechanisms.
1. Pure diffusion
2. Chemical reactions
3. Counter-current diffusion
4. Externally imposed controls
Controlled release polymeric systems can be classified on the basis of the mechanism
controlling the release of the incorporated drug.
DIFFUSION CONTROLLED SYSTEMS
a) Reservoir systems
In these systems, core of the drug is surrounded by a swollen or non swollen polymer
film and diffusion of the drug through the polymer is the rate limiting step. Reservoir
devices are also of two types. Reservoir without a rate controlling system. Reservoirs
that lack rate control include hollow fibers, gels and dialysis tubing. Reservoirs with
rate controlling systems include erodible polymeric matrices, polymer membranes,
monolithic matrices and coated particles25.
b) Matrix systems
In these systems, the drug in uniformly distributed throughout a solid polymer. The
drug diffusion through the polymer matrix is the rate limiting step.
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CHEMICALLY CONTROLLED SYSTEMS
a) Bioerodable System:
In these systems, a drug is uniformly distributed throughout the polymer, and the
drug  is released by diffusion as the polymer phase decreases with time. As the
polymer surrounding the drug resorbed, the drug escapes.
b) Pendant Chain System:
In these systems, the drug is chemically bound to a polymer back bone and drug
release occurs via hydrolytic or enzymatic cleavage.
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2.NEED FOR THE STUDY
In conventional mode of administration many drugs do not reach target areas
in the body  in sufficient concentration because of premature inactivation and
excretion. This problem can be overcome by administering the drug directly to the
intended site of action with lesser dose. In recent years, novel drug delivery systems
are becoming popular as pharmaceutical technologists today are able to provide the
drug delivery systems with very precise control over drug release for a prolonged
period of time eliminating the need for frequent dosing and minimizing side effects,
thereby increasing patient compliance and comfort.
The most common dental infections include dental carries, dental alveolar infections,
gingivitis, periodontitis, deep facial face infections and osteomyelities. If untreated,
dental  infections  spread and contribute to  polymicrobial  infections at  other sites.
Among the above mentioned dental infections periodontitis, a common cause of tooth
lose is one of the chronic infections of oral cavity, primarily caused by gram positive,
gram negative and anaerobic bacteria that reside in sublingual area.
The systemic administration of drugs for treating dental conditions can reach the
systemic circulation via serum and hence the microorganisms at the depth of the
periodontal sites and also the possible organisms residing within gingiva and capable
of eliminating pathogens not only from periodontal lesion but from oral cavity as
well.
The greatest disadvantage of systemic administration of antimicrobials for
periodontitis is that, the drug is diluted several thousand folds before it reaches the
site and exposes the rest of the body to potential side effects. In some patients, loss of
19
attachments develops very rapidly and continuously in spite of proper therapy.
A site specific system aims at delivering the therapeutic agent at sufficient levels
inside the pocket and at the same time minimizing the side effects associated with
systemic drug
20
3.AIMS&OBJECTIVES
The purpose of the present investigation is to develop the polymeric inserts (chitosan)
containing different concentration of the anti-bacterial agent Doxycycline for local
controlled drug delivery into periodontal pockets. Apart from this, an investigational
study is planned to prolong the drug release for more number of days by formulating
in to multilayer (polymer) inserts.
Specific objectives of the present investigation are as follows,
1. To develop a chitosan single layer with different concentration of doxycycline
hyclate (10%, 20% and 30%).
2. To develop a chitosan multilayer inserts containing doxycycline hyclate.
3. Evaluation of prepared inserts for physical characteristics such as
 Thickness and Weight Variation
 Folding Endurance
 Percentage  Moisture Loss
 Percentage Moisture Absorption
 Drug Content Uniformity
 Tensile Strength
 Differential Scanning Calorimetry
 Fourier Transfer – Infrared Spectroscopy(FT-IR)
 Water Uptake and Swelling Index
4. To study static dissolution pattern of the drug dosage forms.
5. In-vitro antibacterial activity.
6. Stability studies at different temperature as per ICH guidelines.
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4. DRUG PROFILE
DOXYCYLINE HYCLATE:
Chemical Name:-(4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)1,4,4a,5,5a,6,
11,12aoctahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene
carboxamide monohydrochloride, compound with ethyl alcohol (2:1), mono-hydrate;
[4S-(4α,4aα,5α,5aα,6α, 12aα)]-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-
3,5,10, 12, 12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene carboxamide
monohydrochloride26.
 Structure:-
 Molecular formula :- (C22H24N2O8 · HCl)2 · C2H6O ·H2O
 Molecular weight :- 444.435 g/mol
 Melting point :- 201-202 0C
 Physical form :- yellow crystalline powder
 Solubility :- Freely soluble in water acetic acid, 6.6 pH buffer and
acetic acid
 Pharmacology:
Tetracyclines are readily absorbed and are bound to plasma proteins in varying
degree. They are concentrated by the liver in the bile, and excreted in the urine and
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feces at high concentrations and in a biologically active form. Doxycycline is virtually
completely absorbed after oral administration.Following a 200 mg dose, normal
adult volunteers averaged peak serum levels of 2.6mcg/ml of doxycycline at 2 hours
decreasing to 1. 45 mcg/ml at 24 hours.
Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with
normal function (creatinine clearance about 75 ml/min). This percentage excretion
may fall as low as 15%/72 hours in individuals with severe renal insufficiency
(creatinine clearance below 10mL/min). Studies have shown no significant difference
in serum half-life of Doxycycline (range 18-22 hours) in individuals with normal and
severely impaired renal function.
Hemodialysis does not alter serum half-life. Results of animal studies indicate that
tetracycline cross the placenta and are found in fetal tissues27.
 Mechanism of action:
Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of
bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the
50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and
inhibiting bacterial protein synthesis. Doxycycline prevents the normal function of the
apicoplast of Plasmodium falciparum, a malaria causing organism27.
 Pharmacokinetics:
1 Absorption Complete, no interference by food
2 Protein binding High
3 Bioavailability 90-95 %
4 Plasma half life 18-22 hrs
5 Metabolism Hepatic
6 Excretion Urine, feces
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 Elimination: Half-life :- 18-22 hours
 Drug interactions:
If used in conjunction with the anesthetic methoxyflurane there can be severe or fatal
kidney damage. May interact with anticoagulants and its effectiveness is lowered by
over the counter antacids and bismuth subsalicylate, barbiturates, the anticonvulsants
carbamazepine and phenytoin. Tetracycline blocks the action of bactericidal
antibiotics such as penicillin and should not be given in combination with such
antibiotics.
 Contraindications:
Doxycycline and other tetracyclines must not be given to women during the last half
of pregnancy or to children under the age of eight. It can affect development of the
skeleton in the fetus and can cause discoloration and malformation of the teeth. Any
demonstrated sensitivity to tetracycline contraindicates use. Some people may show
increased sensitivity to sunlight28.
 Side effects:
Losses of appetite, nausea, vomiting and diarrhea have been observed.
Hypersensitivity, anaphylaxis, and exacerbation of immune disorders have been seen.
Hemolytic anemia and other disturbances of the white cell population of the blood are
known28.
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5.POLYMER PROFILE
CHITOSAN
 Synonyms :- 2-Amino-2-deoxy-(1,4)-β-D-glucopyranan; deacetylated chitin;
deacetylchitin; β-1,4-poly-Dglucosamine; poly-D-glucosamine; poly-(1,4-β-D-
glucopyranosamine).
 Chemical Name and CAS Registry Number :- Poly-β-(1,4)-2-Amino-2-deoxy-
D-glucose [9012-76-4]
 Molecular weight :- 10000-1000000
 Origin of Chitosan
One reason why chitosan has become of interest is undoubtedly because it can be
obtained from natural sources that are abundant and renewable. Chitosan is prepared
from chitin, the polymer second most abundant in nature after cellulose (Roberts,
1992). Chitin is the primary  structural component of the outer skeletons of
crustaceans, and of many other species such as molluscs, insects and fungi. The role
played by chitin is similar to the roles played by cellulose in plants and collagen in
higher animals. It is a reinforcing material, which occurs in three polymorphic forms,
and chitin. Where hardness in needed chitin is found, where flexibility is required and
chitin occurs. Chitin is inert in aqueous environment. This property limits the use of
chitin as such. Chitosan is prepared from chitin to obtain a more reactive polymer29.
Physical Properties
• Particle size < 30nm
• Density 1.35 – 1.49 g/cc
• Solubility: Insoluble in water but soluble in acids.
 pH (1% w/v solution) : 4.0–6.0
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 Solubility:
Sparingly soluble in water; practically insoluble in ethanol (95%), other organic
solvents, neutral or alkali solutions at pH above approximately 6.5.
 Description:
Chitosan occurs as odorless, white or creamy-white powder or flakes. Fiber formation
is quite common during precipitation and the chitosan may look 'cottonlike'.
 Functional Category:
Coating agent, disintegrate, film-forming agent, mucoadhesive, tablet binder,
viscosity increasing agent.
 Structure:
Chitosan is a linear polysaccharide consisting of ß (1-4)-linked 2-amino- 2-deoxy-D-
glucose (D-glucosamine) and 2-acetamido-2-deoxy-D-glucose (N-acetylglucosamine)
units. The structure of chitosan is very similar to that of cellulose (made up of ß (1-4)-
linked D-glucose units), in which there are hydroxyl groups at C2 positions of the
glucose rings30.
 Mechanism of action:
Chitosan formulations can easily be prepared using conventional tableting or
granulating methods. The simplest way of achieving slow release of drugs by means
of chitosan is to employ it as a gel-forming excipient in matrix-type formulations.
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Retardant effects of chitosan on drug release were noticed as early as the 1980s.
Chitosan was found to decrease rates of release  of drugs from tablets during
dissolution tests at acidic and slightly acidic pH levels (Kawashima et al., 1985;
Acartürk, 1989). However, Akbua (1993a), who carried out studies at higher pH
levels (pH 7.4), reported that chitosan exhibited no slow-release properties29, 30.
 Features:
The Chitosan (CS) is known to be non-toxic and odorless. Chitosan has received
considerable attention as a possible pharmaceutical excipient in recent decades
Chitosan is an excellent polymer to be used for buccal delivery because it has
muco/bioadhesive properties and can act as an absorption enhancer. Chitosan gives
prolonged release of the drug in the buccal cavity improving the antimicrobial activity
of the drug. Chitosan periodontal film with drug incorporated have antimicrobial
activity due to the chitosan. The buccal bilayered devices (bilaminated films,) using a
mixture of drugs and chitosan, with or without anionic crosslinking polymers has
promising potential for use in controlled delivery in the oral cavity30.
 Properties of Chitosan:
Cationic Polyamine
Chitosan has highly charged density at pH < 6.5 i.e. one charge per glycosamine unit.
The ionic character along with reactive functional group in chitosan has made it a
suitable polymer for utilization  in controlled release technology. The molecular
weight of chitosan varies from 50 KDa to 2000 KDa29.
Amenable to Chemical Modifications
Chitosan is linear polyamine where amino groups are readily available for chemical
reaction and salt formation with acids. The possibility of amino groups suggests that
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chitosan could be used to formulate therapeutic system where the drug release kinetics
depends on erosion pathway of polymeric network due to hydrolysis of cross-linking
bonds.
Flocculation and Mucoadhesive Properties
Chitosan formulations exhibit ease of delivery [30, 31] a good retention at the
application site, and a controlled release of the drug. Chitosan is shown to have an
antimicrobial activity against P. gingivalis and higher activity with high molecular
weight chitosan.The combination of chitosan with chlorhexidin showed a significant
higher activity, when compared to that of chlorhexidine alone, which would provide
chlorhexidine application at lower concentrations thus avoiding its unwanted side
effects. Chitosan films and gels seem to be promising delivery systems for local
therapy of periodontal diseases with its bioadhesive property and antimicrobial
activity 32.
Biological Properties
Its biological properties include non toxicity, biodegradability and biocompatibility.
N-acyl chitosan showed the best blood biocompatibility due to increase of surface
hydrophilicity and induction in hydrophilic and hydrophobic properties at the surface.
CLINICAL APPLICATION
Wound Healing
Chitin and chitosan are effective wound healing accelerators, in both animal and
human tests, the surgical adjuncts of regenerated chitin are physiologically
compatible, bioabsorbable and effective wound healing accelerators. N-Carboxybutyl
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chitosan was studied in wound healing in rabbits; where complete re-epithelialization
was observed with all the epithelial layers represented on 30th day of treatment, an
interesting role in tissue reconstruction. Chitosan has also been used to prepare
bandages for wound healing.
The physiological compatibility of chitin with living tissues, combined with its ability
to form readily sulfate esters which are non thrombogenic appears to make chitin a
most promising candidate for prosthetic structural devices of any desired shape or
sizes31, 33.
Haemostatic Agent
Chitosan solution formed a coagulum in contact with whole blood, where the possible
mechanism appeared to be a reaction between red cell membrane and the chitosan
solution leading to cross linkage or re-polymerisation. Chitosan is an effective and
adequate homeostatic agent even under the most severe conditions of anticoagulation.
Introduction of uronic acid carboxyl groups increases the anticoagulant activity of
sulfacted chitosan.
Application in Dentistry
Many advantages are attainable by use of chitosan in periodontology such as decrease
subjective symptomatology, good homeostatic action, and delayed release of
antibiotics, wound healing acceleration and better condition for asepsis. Chitosan has
been used in 24 patients all of which recovered completely. No allergic reactions or
infections took place. Chitosan could be used as transparent membrane or preferably
as a thin powder soaked in antibiotic solution, it accelerated wound healing, promoted
regular fibrin formation and favored the epithelialization.
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6. REVIEW OF LITERATURE
REVIEW OF PAST STUDY DONE ON DOXCYCLINE DRUG
 Gaurav Tiwari1 et al., release studies of metronidazole and doxycycline from
polycaprolactone films prepared by solvent evaporation. metronidazole and
doxycycline with different antibacterial spectra are proposed to be formulated as
combination therapy to have a broader antibacterial therapy, which is effective
against both aerobic and anaerobic periodontal microflora. Simultaneous use of
metronidazole and doxycycline is effective against wide range of periodontal
pathogens. Metronidazole and doxycycline release from polycaprolactone films
was zero-order after an initial period. Significant burst effects were observed with
metronidazole and doxycycline (5, 10% w/w) 34.
 Mohammed M Al-Abdaly, et al., studied the effects of topical application of
Atridox (Doxycycline gel) in management of chronic periodontitis. This study
was carried out on 15 patients (aged 25-55) with chronic periodontitis. They were
received scaling and root planning (SRP) alone in one side and SRP plus Atridox
(Doxycycline gel) in other side. Each individual was subjected to the following
measurements. Evaluation of the clinical parameters pre and post treatment to
detect the outcome of the treatment modality and Denial plaque samples initially
and at 3,  6, 9 and 12 months were obtained for microbiological evaluation.
Atridox (Doxycycline gel) delivered locally into periodontal disease sites reduced
all subgingival bacteria. Both treatment and modality led to a highly statistically
significant reduction in microbiological counts as well as clinical parameters
applied. No clinical relevant side effects were observed35.
 Thawatchai Phaechamud et al., studied the chitosan sponges loaded with
Doxycycline hyclate and their antibacterial activities. The pore density of
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chitosan  sponge prepared  with freeze drying  technique was  increased as  the
higher concentration of chitosan solution was used. The sponge prepared from
10% w/w of the chitosan solution and crosslinking with glutaraldehyde solution
was utilized for loading with doxycycline hyclate. The drug release and
sustainable antibacterial activity of fabricated sponge were assessed using
dissolution test and agar diffusion test, respectively. Drug release from  non-
crosslinked sponge into phosphate buffer pH7.4 was slower than that from
crosslinked sponge since the former could absorb the medium and form gel to
retard the initial drug diffusion. Sustainable antibacterial activity of developed
sponge was evident against S. aureus and E. coli. Results indicated that the in
vitro release profile and antibacterial efficiency of doxycycline hyclate could be
sustained using chitosan sponge36.
 N. Damodharan et al., developed delayed release doxycycline tablets for
targeting to small intestine tablets were prepared by wet granulation method and
enteric coating of tablets (conventional standard coating technique). Using pH
depended polymers like Eudragit and HPMC Phthalate. Preformulation studies
like angle  of repose, bulk density, tapped density, porosity, Carr's index,
Hausner's ratio were performed. Six batches (F1 to F6) were formulated and
evaluated for hardness, friability, weight variation, drug content, disintegration
and in‐vitro dissolution. Among the six batches, batch F4 was showed 94% drug
release and was considered as best formulation37.
 S.Shanmuganathan N et al., prepared Doxycycline loaded
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chitosan microspheres were developed using a novel water-in-oil emulsion
technique, involving oil phase ionic gelation. Microspheres were prepared by
using 6% v/v of chitosan (3% w/v in acetic acid), soya oil–n-octanol oil mixture
(1:2 v/v) as continuous phase and 5% span 80 as emulsifier. Doxycycline was
entrapped by equilibrium swelling method with 8.4% total entrapment. The drug-
loaded spheres were spherical with smooth surface morphology. The MTT assay
showed that doxycycline-loaded microspheres were able to improve the
percentage cell viability in comparison to the pure drug. In vitro release studies
showed that a burst release of 42% in 6 h was achieved and maintained an
equilibrium concentration of 72% in 24 h. Assessment of antibacterial activity
showed that doxycycline was able to exhibit a minimum microbicidal
concentration (MIC) of 16.5, 17.4, 11.2 and 98.3μg against Klebsiella
pneumoniae (ATCC15380), Escherichiacoli (ATCC25922), Staphylo
coccusaureus (ATCC9144) and Pseudomonas aeruginosa (ATCC 25619),
respectively. Gelatin zymography studies revealed that it could inhibit MMP 2
and MMP9 at sub-antimicrobial concentration. The present investigation provides
scope for using doxycycline-loaded chitosan microspheres for healing
infected wounds39.
 MarcoAntonio Botelho etal., aim of this study was to test the efficacy of a
locally applied 8.5% nanostructure doxycycline (DOX) gel in preventing alveolar
bone loss in experimental periodontal disease (EPD) in rats by using the tapping
mode atomic force microscopy (AFM). Material and method EPD was induced in
24 Wister rats. Animals were treated with the doxycycline gel topically,
immediately after EPD induction, and 3 times a day during 11 days. Four groups
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(n=6) were formed as follows: each group (animals not subjected to EPD nor
treated); non-treated (NT) group (animals subjected to EPD, but not treated);
vehicle gel (VG) group (animals subjected to EPD and treated with topical gel
vehicle); and DOX group (test group) animals subjected to EPD and treated with
the 8.5% DOX gel. In order to investigate topographical changes in histological
sections, a novel simple method was used for sample preparation, by etching
sections from paraffin-embedded specimens with xylol. Results: comparing the
AFM images, several grooves were observed on the surface of the alveolar bone
and other periodontal structures in the NT and VG groups, with significantly
greater depths when compared to the DOX group40.
 Narayana Charyulu et al., developed strips of chitosan polymer 2% containing
ciprofloxacin Hcl, norfloxacin and doxycycline by solution casting method using
1% acetic acid as casting solvent. Macroscopical features revealed that drugs
were dissolved in the polymer. The DSC and UV scan studies confirmed the
absence of any chemical interaction between the drugs and polymer. Short term
stability studies were carried out at different temperature. The static dissolution
showed a burst release effect initially followed by  a progressive fall in the
release. Mass balance studies did not deviate by more than 3%. It was observed
from the above studies that the chitosan strips have an ability to sustain the
release of drugs and more useful as slow release device for periodontal disease41.
 Heba A. Gad et al., formulated in situ implants containing doxycycline
hydrochloride and/or secnidazole that could be used in the treatment of
periodontitis by direct periodontal intrapocket administration. Biodegradable
polymers [poly (lactide) (PLA) and poly (lactide-co-glycolide) (PLGA)], each
polymer in two concentrations 25%w/w, 35%w/w were used to formulate the
33
insitu implants. The rheological behavior, in vitro drug release and the
antimicrobial activity of the prepared implants were evaluated. Increasing the
concentration of each polymer increases the viscosity and decreases the percent
of the drugs released after 24 h. PLA implants showed a slower drugs release rate
an PLGA implants in which the implants composed of 25% PLGA showed the
fastest drugs release. The in vitro drug release and antimicrobial activity results
were compared with results   of Atridox®. Results revealed   that   the
pharmaceutical formulation based on 25% PLGA containing secnidazole and
doxycycline hydrochloride has promising activity in treating periodontitis in
comparison with Atridox42.
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PAST WORK DONE ON POLYMER (CHITOSAN)
 Shankraiah et al. were prepared Flexible films of sparfloxacin for periodontitis
treatment for easy insertion into periodontal pockets. The optimum concentration
of chitosan used for the preparation of strips was found to be 2% w/v, because at
this concentration the strips were flexible and easily removable from the die. An
optimum concentration of drug to be loaded was found to be 30% w/v to the
polymer or less than that. For the present investigation, chitosan strips containing
sparfloxacin with three different concentrations, i.e.10, 20, and 30% to the weight
of the polymer, were prepared using the solvent casting method. All the
formulations were found to contain almost uniform quantity  of drug as per
content uniformity studies, indicating reproducibility of the technique43.
 Dan Mei et al., The objective of this work was to assess and compare the
absorption promoting effect of different molecular-weight chitosans, trimethyl
chitosans and thiolated chitosans for intranasal absorption of 2,3,5,6-
tetramethylpyrazine phosphate (TMPP). An in situ nasal perfusion technique in
rats was utilized to test the rate and extent of TMPP absorption in situ. In vivo
studies were carried out in rats and the pharmacokinetic parameters were
calculated and compared  with  that  of intravenous  injection.  All  the chitosan
derivatives investigated could enhance the intranasal absorption of TMPP
significantly. However, thiolation could not improve the absorption-enhancing
capacity of chitosan remarkably even when the thiolation ratio was as high as
152 lmol/g. In contrast, trimethylated chitosan exhibited stronger absorption-
enhancing ability than the homopolymer chitosan. The permeation enhancing
effect of chitosan increased with increasing molecular weight up to Mw 100 kDa.
In vivo studies indicated that chitosan 100 kDa and TMC 50 kDa had comparable
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absorption-enhancing effect but chitosan 100 kDa functioned for more than 120
min versus 90 min for TMC. A good correlation was found between the in situ
absorption data and plasma concentration in vivo for the polymers investigated.
This study demonstrated that both chitosan structural features and chitosan
molecular weight play  a key role on promoting  the intranasal absorption of
TMPP. Taking safety reason into account, chitosan 100 kDa is the most
promising as an intranasal absorption enhancer.44.
 Barat R et al., chitosan based  metronidazole inserts  were fabricated by the
casting method and characterized with respect to mass and thickness uniformity,
metronidazole loading and in vitro metronidazole release kinetics. The fabricated
inserts exhibited satisfactory physical characteristics. The mass of inserts was in
the range of 5.63 ± 0.42 to 6.04±0.89 mg. The thickness ranged from 0.46 ±0.06
to 0.49 ±0.08 mm. Metronidazole loading was in the range of 0.98 ±0.09 to
1.07±0.07 mg except for batch CM3 with MZ loading of 2.01V± 0.08. The
inserts exhibited an initial burst release at the end of 24 hr, irrespective of drug to
polymer ratio plasticizer content or cross linked. However further drug release
was sustained over the next 6 days, cross linking to 10% (m/m) of glutaraldehyde
inhibited the burst release by~30 % and increased the mean dissolution time
(MDT) from 0.67 to 8.59 days. The decrease in drug release was a result of
reduced permeability of chitosan due to cross linking45.
 Senel S, IkicI G.et.al., developed the formulation containing chitosan for local
delivery of chlorhexidine gluconate (chx) to the oral cavity. Gels at (1 or 2%
concentration) or film forms of chitosan were prepared containing 0.1-0.2% chx
(chlorhexidine gluconate) and there in vitro release properties were studied. The
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antifungal activity of chitosan itself as well as their various formulations
containing chlorhexidine gluconate (chx) was also examined. Release of
chlorhexidine gluconate (chx) from gels was maintained for 3hr. A prolong
release was observed with film formulation. No lag time was observed in release
of chx from either gels or films. The highest antifungal activity was obtained with
2% chitosan gel containing 0.1% chlorhexidine gluconate (chx.)46.
 Amal Hassan El-Kamel et al., developed a local, oral mucoadhesive
metronidazole benzoate (MET) delivery system that can be applied and removed
by the patient for the treatment of periodontal diseases. Mucoadhesive
micromatricial chitosan poly(ε-caprolactone) (CH/PCL) films and chitosan films
were prepared. Thermal behavior, morphology, and particle size measurements
were used to evaluate the prepared films. The effect of different molar masses of
CH and different ratios of medium M.wt.molar mass chitosan (MCH): PCL on
water absorption, in vitro bioadhesion, mechanical properties, and in vitro drug
release was examined47.
 Ritu B. Dixit et al., developed cefadroxil drug loaded biopolymeric films of
chitosan-furfural schiff base were prepared by reacting chitosan with furfural in
presence of acetic acid and perchloric acid respectively for the external use.
Prepared films were evaluated for their strength, swelling index, thickness, drug
content, uniformity, tensile strength, percent elongation, FTIR spectral analysis
and SEM. The results of in vitro diffusion studies revealed that the films
exhibited enhanced drug diffusion as compared to the films prepared using
untreated chitosan. The films also demonstrated well to moderate antibacterial
activities against selective gram positive and gram negative bacteria48.
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 Mohammed Gulzar Ahmed et al, developed chitosan strips containing
Gatifloxacin (10%, 20% and 30% to the weight of polymer) were prepared by
solution casting method using 1% v/v acetic acid in water. Further strips
containing 30% gatifloxacin were cross-linked by exposing to the vapours of 2%
v/v glutaraldehyde in water intended to extend the release. The prepared films
were evaluated for their thickness, content uniformity, weight variation, tensile
strength, hardness and in-vitro dissolution. The average weight and thickness of
both the cross linked and uncross-linked strips were uniform. There was a
reduction in the tensile strength and increase in hardness when the films were
cross-linked. Static dissolution studies showed a burst release initially followed
by a progressive fall in the release of the drug and extended up to 19 days once
the strips were cross-linked. Release kinetics of gatifloxacin from chitosan strips
followed the higuchi’s diffusional model and also showed zero order release
profile49.
 S.Sangeetha et al., Nanoparticle made up of biodegradable carrier such as
chitosan have advantage of providing stearic interference in the systemic
circulation. Cytarabine nanospheres were prepared by ionic gelation method with
an objective of improving its intracellular targeting and thereby targeting the
cancer cells. The average particle size determined through SEM was found to be
466.45 ± 5.32 nm. The average drug loading was found to be 62% for the batch
loaded with 1.50 mg/ml of drug when compared to other batches. The cumulative
percentage of drug release from all the drug loaded batches at 18 hours was found
to be in the range of 86.73 % to 93.50%.Among the four batches of nanoparticles
formulated the batch containing  1.50mg  of drug/ml of polymer showed the
highest of about 93.50% of release. Release of drug from the matrix was by non-
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Fickian analomous diffusion mechanism. Invivo bio distribution studies showed
that the Cytarabine in the form of nanoparticles was having a greater bio
distribution when compared to free drug in different organs like liver, spleen,
lungs and kidney50.
 K. Bansal et al., develop  satranidazole-containing mucoadhesive gel for the
treatment  of periodontitis.  Different  mucoadhesive gels  were prepared, using
various gelling agents like sodium carboxymethylcellulose (SCMC), poloxamer
407, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methyl
cellulose, and the mucoadhesive polymer carbopol 934P. The selected
formulations were studied for different mechanical properties, such as
mucoadhesive  strength, hardness, compressibility, adhesiveness, and
cohesiveness through texture profile analyzer. In vitro satranidazole release from
the prepared formulations was also determined and compared  with marketed
preparation  of metronidazole.  The formulation SC30 (Containing SCMC 3%
w/v)   showed maximum mucoadhesive strength (167.72 ± 3.76 g) and
adhesiveness (−46.23 ± 0.34 Nmm), with low hardness (9.81 ± 0.04 N) and
compressibility (40.05 ± 0.48 Nmm) and moderate cohesiveness (0.87 ± 0.01).
SC30 formulation exhibited long-term release. Thus, SC30 gel was evaluated for
its clinical effectiveness along with marketed metronidazole gel. At the end of the
study (42 days of clinical studies), both formulations were found to significantly
reduce the probing depth, plaque index, gingival index, calculus criteria, and
bleeding index. However, the SC30 gel was more effective in reducing the above
parameters than marketed metronidazole gel. This study confirmed the
acceptability and effectiveness of satranidazole gel for treatment of
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periodontitis.51.
 Mohammed Gulzar Ahmed et al., prepared Chitosan films containing
tetracycline in three different concentrations were prepared by  the solution
casting method, using 1% v/v acetic acid solution for therapy of periodontal
disease. The prepared films were evaluated for various properties. The stability
studies did not show any significant changes. Static dissolution studies showed a
burst release initially followed by a progressive fall in the release of the drug, and
also showed extended release when cross-linking was attempted. The in-vitro
release kinetics of tetracycline followed the zero order patterns52.
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REVIEW STUDY DONE ON LOCAL DRUG DELIVERY SYSTEM
 Shankraiah et al., developed a sustained release device containing ornidazole for
insertion within periodontal pockets. Cast films of ethyl cellulose with dibutyl
phthalate as plasticizer, containing ornidazole were prepared. The films  were
evaluated for thickness, folding endurance, weight variation, content uniformity,
tensile strength, in vitro antibacterial activity and in vitro release study.   The
release data obtained were subjected for release kinetics study. The study revealed
that drug release was found to be diffusion controlled with sustained release of
ornidazole over a period of nine days within the periodontal pocket53.
 G.L.Prabhushankar et al., developed a levofloxacin dental films for periodontitis
between levofloxacin and  polymers.The films were evaluated for their thickness
uniformity, folding endurance, weight uniformity, content uniformity, tensile
strength, surface pH and in vitro antibacterial activity54.
 Mastiholimath V.S et al., site specific one time delivery of ornidazole an
antimicrobial compound with excellent activity against anaerobic micro-organism
in the treatement of periodontal disease was prepared by solvent casting technique
using ethyl cellulose, hydroxyl propyl cellulose, hydroxypropylmethyl cellulose
K4M and eudragit RL-100 With dibutyl phthalate is plasticizer.The
physiochemical parameters like thickness, weight variation, content uniformity
and release characteristics were evaluated. The drug release was initially high on
day one to achieve immediate therapeutic level of drug in pocket, followed by
marked fall in release by day two and progressive moderate release profile to
maintain therapeutic level following anomalous transport release profile
mechanism. Formulation V6 released 97.07 % of drug at the end of 120 hour
and was considered as best formulation. In vitro antibacterial activity was carried
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out on Streptococcus Mutans55.
 Hong Hua., Chi ping.et al., prepared multilayer membranes which were loaded
with drug for guided tissue regeneration were prepared using an immersed
precipitation phase   inversion technique, single   layer, bilyer and trilayer
mechanism were fabricated with chitosan used as carrier and tinidazole as
medicine model which was loaded on the membrane. The influence of layer on
structure and properties of membrane were studied by SEM, UV spectrometer
and mechanical test. Drug release properties of three types of layer membrane
also investigated. The result showed that release rate could be shown in both
bilayer and trilayer membrane (11 days and 14 days respectively) and trilayer
membrane lastest the longest. After a process of rapid release, the concentration
of tinidazole which was released by the membrane was maintained at an efficient
dosage level compared with single  layer and bilayer membranes, be found
trilayer membrane could play  a role in controlling  low rate drug release
especially at the early stage of release, and keep an efficient dosage at affected
part for a long period of time. The loss of drug which loaded on membrane
decreased from 84.6% for Single layer to 13.04% for trilayer the mechanical
strength of three types of membrane were detected an showed that it could meet
the requirements of clinical practice the membranes specially with trilayer could
be more valuable in application56.
 Sujatha Muchalambet al., Specific one time continuous delivery of sparfloxacin
an antimicrobial compound with excellent activity against anaerobic micro-
organisms in the treatment of periodontal disease was prepared by using solvent
casting technique using hydroxy propyl cellulose, hydroxy methyl cellulose,
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eudragit RL-100 and ethyl cellulose with dibutyl phthalate as plasticizer. The
physicochemical parameters like thickness, weight variation, content uniformity
and release characteristics were evaluated. The drug release was initially high on
day one to achieve immediate therapeutic level of drug in periodontal pocket
followed by marked fall in release by day two with progressive moderate release
profile to maintain therapeutic level following anamolous transport mechanism.
Formulation F4 released 90.24% of drug at the end of 120 hr and was considered
as best formulation. In vitro antibacterial activity was carried out on
Streptococcus mutans57.
 K. Schwach-Abdellaoui et al., Periodontitis is an inflammatory disease of the
supporting tissues of the teeth caused by groups of specific microorganisms.
Aggressive forms of periodontitis can be localized or generalized. The concept
that localized problem sites may be treated by local drug delivery appears
attractive as the antimicrobial agent is delivered within periodontal pockets and
the therapy is targeted on specific pathogenic microorganisms. Local delivery of
antimicrobial agents using controlled release systems should be considered as
adjunctive to mechanical debridement for the treatment of localized forms of
periodontal destruction. This article reviews various types of delivery systems
evaluated in practical periodontal therapy. Despite the large number of studies
showing an enhanced effectiveness of local antibiotherapy, there are insufficient
Comparative data to support any of the local delivery system58.
 Vineet Bhardwaj et al., Chitosan films of different concentrations containing
ofloxacin were prepared by solvent casting method. Some of the drug-loaded
films were crosslinked with 2% gluteraldehyde for 1,2 and3 hrs, respectively.
The films were then evaluated for their physicochemical properties including
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weight variation, thickness, moisture loss, tensile strength, elongation, in vitro
anti bacterial activity and in vitro release. In vitro drug release data indicate that
the films showed an initial burst release followed by sustained release of the
drug. The drug-loaded films that were not crosslinked had effect on for up to 9
days and the films which are crosslinked for different duration shows release
depended on concentration of chitosan in different films (1%, 2%, 3%)59.
 Steinberg et al., developed a degradable sustained release device composed of a
cross linked protein containing chlorhexidine. The in-vitro release profile of
chlorhexidine (from the degradable films) was altered by the amount of
chlorhexidine loaded, cross- linking density of the polymer and type of
chlorhexidine salt. This work demonstrated the release of chlorhexidine and
showed that the degradation of the matrix can be controlled by factors in the
formulation60.
 Hitzig et al., observed 28 patients suffering from adult periodontitis for a span of
3 months. They treated the patients with 5% metronidazole in collagen device in
periodontal pocket more than 5 mm, keeping mechanical root debridement as
control. Analysis of data from 28 patients indicated that both debridement and
metronidazole therapy decrease pocket depth, bleeding on probing and gingival
index, but results were significantly better with metronidazole61.
 Kurien et al., evaluated the efficacy of ciprofloxacin and norfloxacin when used
in a sustained release system in periodontal pockets. Sustained release inserts
were prepared using ethyl cellulose (EC) and hydroxypropyl methyl cellulose as
(HPMC) co-polymers along with polyvinyl pyrrolidine (PVP), drug and ßeta
cyclodextrin complex. The rate of release of the drug was controlled and
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prolonged for 14 days period. It was found that both norfloxacin and
ciprofloxacin appeared to be equally effective in reducing periodontal pathogens
and in controlling the inflammation compared with the placebo treated control
sites62.
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7. MATERIAL AND METHODS
MATERIALS
Drug, Polymer and Chemicals:
S.No Name of the Chemicals Supplier Name
1. Doxycycline hyclate Micro labs, Banglore.
2. Chitosan Central Institute of Fisheries Technology ,
Metysapuri,Cochin.
3. Acetic acid S-difine Chemicals., Mumbai
4. Potassium hydrogen ortho
Phosphate
S-difine Chemicals., Mumbai
5. Sodium hydroxide S-difine Chemicals., Mumbai
6. Glutaraldehyde S-difine Chemicals., Mumbai
7. Calcium chloride S-difine Chemicals., Mumbai
8. Anhydrous aluminum chloride S-difine Chemicals., Mumbai
9. Acetone S-difine Chemicals., Mumbai
All the other chemicals used in this study are of analytical reagent grade (A.R. grade).
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List of Instruments Used For Formulation and Evaluation
S.No Instruments Supplier
1. UV/Visible Spectrophotometer 1700 Shimadzu
2. Vortex mixer VM 301 Remi., Mumbai
3. Digital pH meter HANNA Instruments, Italy
4. Electronic weighing Balance Essaie-Teraoka Ltd., USA
5. Tensile strength tester Digital testing apparatus
6. Digital screw gauge Mitutoyo., Japan
7. FT-IR Shimadzu
8. Levelled glass moulds Designed in our laboratory
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4. EXPERIMENTAL METHODS:
1. PREFORMULATION STUDIES
Preformulation testing is the first step in the rational development of dosage form of
the drug. It can be defined as an investigation of physical and chemical properties of
drug substances, alone and when combined with excipents. The overall objective of
preformulation testing is to generate information useful to the formulator in
developing stable and bioavailable dosage forms, which can be mass produced.
A thorough understanding of physicochemical properties may ultimately
provide a rational for formulation design or support the need for molecular
modification or nearly conform that there are more significant barriers to the
compounds development. The goals of the program therefore are to establishment
the necessary physicochemical characteristics of new drug substances
 Determine its kinetic release rate profile.
 To establish its compatibility with different excipents.
Hence, preformulation studies on obtained drug sample include physical tests and
compatibility studies.
 Melting Point determination:
Melting point was determined by taking small amount of drug in a capillary tube
whose one end was sealed by melting. The capillary tube was placed in the Digital
melting point apparatus.   The temperature was slowly increased with simultaneous
observation of the sample.   The temperature at which the drug starts melting was
recorded as melting point. This process was performed three times for Doxycycline.
The mean of three readings was recorded.
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2. COMPATIBILITY STUDIES
Drug- Excipient interaction studies:
The successful formulation of a stable and effective solid dosage form depends on the
careful selection of the excipients that are added to facilitate administration, promote
the consistent release and bioavailability of the drug.
FTIR and DSC studies can be used to investigate and predict any physicochemical
interactions between components in a formulation and can therefore be applied to the
selection of suitable chemically compatible excipients.
a. Fourier transforms infrared (FTIR) Spectral studies:
FTIR spectra were taken on a Shimadzu instrument to investigate the  possible
chemical interactions between the drug and the blend matrix. FTIR spectra of plain
doxycycline and physical mixture were scanned in the range between 4000 and 500
cm-1. The spectra’s are compared with the peak intensities found in a standard
reference.
Sample preparation
Samples are taken in the ratio of 1:100, where 1 is the amount of sample taken and
100 was the amount of potassium bromide taken and triturated with due precaution
not to contact with the moisture, which may interfere with the test. Samples were
crushed with KBr to get the pellets by applying a pressure of 300 kg/cm2. The sample
along with blank (KBr), reference standard drug are placed in order on the disk
provided. Peaks obtained in FTIR are compared to that of standard peaks for any
significant change64.
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b. Differential scanning calorimetry (DSC):
The DSC measurements were performing on a DSC – 61000 (Seiko Instruments,
Japan) differential scanning colorimeter with thermal analyzer. All accurately
weighed samples (about 5 mg of doxycycline and chitosan) were placed in a sealed
aluminum pans, before heating under nitrogen flow (20 ml/min) at a scanning rate of
200C per min from 100 to 3000C.  An empty aluminum pan was used as reference65.
3. ANALYTICAL METHODS
a. PREPARATION OF REAGENTS
Preparation of 1% v/v acetic acid:
Accurately measured 1 ml of concentrated acetic acid was dissolved in 100 ml of
distilled water.
Potassium dihydrogen orthophosphate 0.2M:
Dissolved 27.218 grams of potassium dihydrogen orthophosphate in distilled water
and volume adjusted to produce 1000 ml.
Sodium hydroxide 0.2 M:
8.0 grams of NaOH was dissolved in distilled water and volume adjusted to produce
1000 ml63.
Table no.4.1: Preparation of 6.6 pH phosphate buffer solution
pH Potassium hydrogen
phosphate solution
0.2M(ml)
NaOH 0.2M
Solution (ml)
Adjusted (ml) to
6.6 50 16.4 200
50
b. Preparation of Standard Stock Solution:
Standard stock solution of doxycycline hyclate was prepared by dissolving accurately
weighed 100mg of doxycycline hyclate in small quantity of 6.6 pH phosphate buffer
in 100ml volumemetric flask. The volume was made up to 100ml by using 6.6 pH
buffer to obtaine the solution of 1000µg/ml.
c. Determination of Analytical Wavelength:
Scanning of Doxycycline Hyclate by UV Spectrophotometer:
From the standard stock solution 4ml was pipetted out into 100ml of volumemetric
flask. The volume was then made up to 100ml with 6.6 pH phosphate buffer. The
resulting solution containing 40µg/ml was scanned between 200-400nm and scan is
shown in Figure no.6.1.
Calibration Curve of Doxycycline Hyclate in 6.6 pH Phosphate Buffer:
From the standard stock solution of doxycycline hyclate (40µg/ml), Appropriate
liquates were taken in to different volumetric flask and volume made up to 10ml with
6.6 pH phosphate buffer, so as to get solution with drug concentration of 4 to 24
µg/ml. The absorbencies of the drug solution were measured at 274nm.These
procedure was performed six times to validate the calibration curve. The data are
given in Table no.6.1. The calibration curve constructed is showed in Figure no.6.2.
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4. PREPARATION OF INSERTS
Inserts were prepared by using antimicrobial agent Doxycycline hyclate and polymer
chitosan by solvent casting method.
a. Preparation of drug loaded chitosan inserts:
The general flow diagram for the preparation of chitosan inserts was given in figure
4.1. Chitosan (2% w/v) was soaked in acetic acid (1% v/v in water) for 24 hours to
get a clear solution. This dispersion was filtered through a muslin cloth to remove
undissolved portion of the polymer (chitin). Required amount of the drug was added
and vortexed for 1-2 hrs to dissolve the drug in chitosan solution. The viscous
dispersion was kept aside for complete expulsion of air bubbles. The films were
casted by pouring the drug-polymer dispersion into the center of leveled glass moulds
and allowed to dry at room temperature (30°C) for 24 hours. After drying, films were
cut into inserts of required size (7 × 2 mm). Inserts containing zero percent (placebo),
10%, 20% and 30% w/w of the drugs to the weight of polymer were prepared These
were wrapped in aluminum foil and stored in desiccators until further use 56.
b. Preparation of bi-layer inserts:
15 ml 2% chitosan cast solution without drug was poured into mould and dry at room
temperature to form the first layer of bi-layer membrane. 20 ml chitosan cast solution
with 30% drug was cast on the first layer and it was dried to room temperature. Then
the dried inserts were kept in desiccators for further study56.
c. Preparation of tri-layer membrane:
15 ml of 2% chitosan cast solution without drug was cast into mould and then dried to
room temperature to form the down layer of the tri-layer. 20 ml chitosan cast solution
with 30% drug was cast on the down layer after it was dry to form the middle layer of
the tri-layer. And then 15 ml of 2% cast solution without drug was cast onto the
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previous membrane also after it had been dry again to form the upper layer of the tri-
layer. Then dried inserts were kept in desiccators for further use.
Table No. 4.2: Composition of different periodontal inserts
Inserts Inserts code % of drug loaded
Plain Inert CP 0
Single layer DSL-10 10
Single layer DSL-20 20
Single layer DSL-30 30
Bilayer insert DBL-30 30
Trilayer insert DTL-30 30
CP = Chitosan polymer, DSL-10, 20, 30= Doxycycline single layer with 10%, 20% and 30%, DBL-30
=Doxycycline bilayer with 30% and DTL-30= Doxycycline trilayer with 30%.
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24
Chitosan + 1% v/v acetic acid
Kept aside for
4 hours
Vortexed for
15 minutes
Viscous solution of chitosan
Filtered
Clear solution of chitosan
Drug Vortexed for
15 minutes
Viscous solution of drug
in polymer (chitosan)
Air bubbles were
removed, by keeping
aside
Pouring in the
die
Drying at room
temperature
(30 ± 2° C)
Removed from the die and
stored in the desiccators
Figure No. 4.1: Protocol for the Preparation of Drug Loaded Chitosan Inserts
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5. CHARACTERIZATION OF THE POLYMERIC INSERTS
All the prepared periodontal inserts were evaluated for various parameters like
thickness, weight variation, folding endurance, tensile strength, drug content, in vitro
release, swelling index, in-vitro anti microbial activity and stability studies.
a) Thickness Measurement:
The thickness of the polymer inserts (2x7 cm) was measured by using a digital screw
gauge (Mitutoyo) at different areas of the inserts and the average was calculated53.
b) Weight Variation:
The weight variation test was carried out by weighing 6 inserts cut from different
places of same formulation and their individual weights were determined by using the
digital balance. The mean valve was calculated. The standard deviations of weight
variation were computed from the mean value53.
c) Folding Endurance Studies:
Folding endurance of the inserts was determined by repeatedly folding the insert at
the same place till it broke or folded. The number of times, the insert could be folded
at the same place, without breaking, gave the value of folding endurance53.
d) Tensile Strength Measurement:
Tensile strength of the inserts was determined by Universal strength testing machine.
It consists of two load cell grips, the lower one is fixed and upper one is movable. The
test inserts of specific size (2 × 2 cm) was fixed between these cell grips and force
was gradually applied till the film breaks. The tensile strength of the inserts was taken
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directly from the dial reading in kilograms Measurements were run in triplicate for
each film53.
Figure No. 4.2: Digital Tensile Strength Measurement Instrument.
e) Estimation of Drug Content:
The drug loaded chitosan insert of known weight (7 × 2 mm) were dissolved in small
volume of 1% (v/v) acetic acid and drug solution was suitably diluted with 6.6 pH
phosphate buffer and the absorbance was measured at  274nm53.
f) Percentage Moisture Absorption:
The percentage moisture absorption test was carried out to check physical stability or
integrity of the inserts. Periodontal inserts of known size were weighed and placed in
a dissector containing 100ml of saturated solution of aluminum chloride and 79.5%
humidity was maintained. After three days the inserts were taken out and reweighed.
The percentage moisture absorption was calculated using the formula.
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% Moisture absorbance = Final weight – Initial weight      x 100
Initial weight
g) Percentage Moisture Loss:
The percentage moisture loss test was carried out to check physical stability or
integrity of the inserts. Periodontal inserts of known size were weighed and placed
in a dissector containing 100ml of saturated Calcium chloride and 79.5% humidity
was maintained. After three days the inserts were taken out and reweighed. The
percentage moisture loss was calculated using the formula.
% Moisture Loss = Initial weight – Final weight      x 100
Final weight
h) Determination of Water Uptake and Swelling Behavior:
Water uptake was determined gravimetrically. Drug loaded inserts were placed on
a filter paper. The lower side of filter paper was immersed in a beaker containing
6.6 pH phosphate buffer, and incubated at 30 0C. Weight of each inserts was
determined with digital weight balance at predetermined time points. The size
changes of the inserts due to swelling investigated macroscopically.
i) In-Vitro Antibacterial activity:
In-vitro antibacterial activity was performed on all formulation by placing the
insert (2x7) on agar plates seeded with oral bacteria steptococuss mutans. After 48
hrs of incubation at 37 0C, the inserts were transformed to freshly seeded agar
plates and incubated for additional 48 hrs. This procedure was repeated until no
inhibition of bacterial growth was detected on agar plate. The growth inhibition
zone on the agar plate was measured.
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j) In-vitro Release Studies:
Since the pH of the gingival fluid lies between 6.5 – 6.8, phosphate buffer pH 6.6 was
used as simulated gingival fluid for the dissolution studies and the inserts remains
immobile in the periodontal pocket, a static dissolution model was adopted.
A static dissolution method reported in the literature was adopted in this thesis. Sets
of 3 inserts of known weight and dimension (7 × 2 mm) were placed separately into
small test tubes containing 1.0 ml phosphate buffer, pH 6.6. The tubes were sealed
and kept at 37°C ±1 for 24 hours. The buffer was then drained off and replaced with a
fresh 1.0 ml phosphate buffer pH 6.6. The concentration of drug in the buffer was
measured at 274nm .The procedure was continued for consecutive days53.
6. DEPENDENT-MODEL METHOD (KINETIC MODELING):
The results obtaining in vitro release studies were plotted in different models of data
treatment as follows:
ZERO ORDER KINETIC
It describes the system in which the drug release rate is independent of its
concentration.
Qt = Qo + Ko t
Where,
Qt= Amount of drug dissolved in time t
Qo = Initial amount of drug in the solution, which is often zero and
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Ko = zero order release constant.
If the zero order drug release kinetic is obeyed, then a plot of Qt versus t will give a
straight line with a slope of Ko and an intercept at zero.
FIRST ORDER KINETIC:
It describes the drug release from the systems in which the release rate is
concentration dependent.
Mt / M∞ = ktn
Log [Mt / M∞] =   log k + n
Where,
Qt = amount of drug released in time t.
Qo = initial amount of drug in the solution
k = first order release constant
If the first order drug release kinetic is obeyed, then a plot of log (Qo- Qt) versus t
will be straight line with a slope of kt / 2.303 and an intercept at t=0 of log Qo.
HIGUCHI MODEL:
It describes the fraction of drug release from a matrix is proportional to square root of
time.
Log Qt = log Qo + kt / 2.303
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Where,
Mt and M∞ are cumulative amounts of drug release at time t and infinite time, and
kH = Higuchi dissolution constant reflection formulation characteristics.
If the Higuchi model of drug release (i.e. Fickian diffusion) is obeyed, then a plot of
Mt / M∞ versus t1/2 will be straight line with slope of kH.
KORSMEYER-PEPPAS MODEL (POWER LAW):
The power law describes the drug release from the polymeric system in which release
deviates from Fickian diffusion, as expressed in following equation.
Mt / M∞= kHt1/2
Where,
Mt and M∞ are cumulative amounts of drug release at time t and infinite time
(i.e. fraction of drug release at time t),
k = constant incorporating structural and geometrical characteristics of CR d
device,
n = diffusional release exponent indicative of the mechanism of drug release
for drug dissolution.
• To characterize the release mechanism, the dissolution data {Mt / M∞ <0.6} are
evaluated.
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• A plot of log {Mt / M∞} versus log t will be linear with slope of n and
intercept gives the value of log k.
• Antilog of log k gives the value of k.
• Peepas used the n value in order to characterize different release mechanisms as
shown in the table below,
Table No.4.3: Release Mechanism of Peppas
‘n’ MECHANISM
0.5 Fickian diffusion
0.5 < n <1 Non- fickian diffusion
1 Class II transport
Stability Studies:
The stability of the drug loaded polymer inserts were studied at different temperatures
using the reported procedure. The 3 inserts of size (7 × 2 mm) were weighed. The
strips were wrapped in aluminum foil and placed in petridishes. These container was
stored at ambient humid conditions, at room temperature (27 ± 2°C), oven
temperature (40 ± 2°C) and in refrigerator (5 - 8°C) for a period of 3 months. The
samples were analyzed for physical changes such as color and texture.
The drug content was estimated at an interval of 1 month using the procedures
reported earlier in this thesis53.
The results obtained from these methods and the discussion of the obtained results is
given in the following chapter “Results and Discussion”.
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8.RESULT AND DISCUSSION
Periodontal inserts were prepared by solvent casting method and inserts were
characterized for various parameters like thickness, weight variation, swelling index,
moisture absorption, folding endurance, tensile strength, percentage moisture loss,
drug content, stability study and in-vitro release studies. Table no.4.2 shows
composition of various formulations of periodontal inserts with aimed at providing
local long term release of Doxycycline (DCL).
1. PREFORMULATION STUDIES
The following preformulation studies were performed for drugs and polymer.
Determination of Melting Point:
Melting point was determined and it was found to be 2020- 2030C ±20C (N =3). This
value is very close to that of literature citation. Thus, indicating purity of the drug.
2. EXPERIMENTAL METHODS
a) Analytical Methods
Determination of λ max:
Absorption spectrum of doxycycline hyclate was obtained using phosphate
buffer pH 6.6 by scanning the sample in UV spectrophotometer in the range of 200-
400 nm. The absorption maxima were found to be at 274 nm and the spectra is shown
in the figure no.6.1.
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Figure No.6.1: Analytical Wavelength of Doxycycline Hyclate.
Calibration Curve of Doxycycline:
Table no.6.1 shows the absorbance reading of DCL. Standard solutions containing
4- 24 µg/ml in phosphate buffer pH 6.6. Figure no. 6.2 shows standard calibration
curve for DCL with the correlation coefficient of 0.997. The drug content uniformity
and in vitro drug release study are based on this calibration curve. The absorbance
was measured at λ max of 274 nm.
Table No. 6.1.: Calibration Data of Doxycycline hyclate in 6.6 pH Phosphate
Buffer.
SL.NO. CONCENTRATION
(µg/ml)
ABSORBANCE*
AM ±SD
1 4 0.157 ± 0.002
2 8 0.264 ± 0.005
3 12 0.413 ± 0.006
4 16 0.523 ± 0.001
5 20 0.684± 0.028
6 24 0.778 ± 0.007
Each value is an average of six replications* R2=0.997
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Figure No.6.2: Calibration Curve of Doxycycline in pH 6.6 Phosphate Buffer.
3.    DRUG EXCIPIENT COMPATIBILITY STUDIES
• Fourier Transform Infrared Spectroscopy (FT-IR) studies:
The preformulation studies between the drug and formulation component under
the experimental conditions were done by using IR spectrum and was recorded on
shimadzu FT-IR by preparing KBr disc. The entire characteristics peak obtained in the
spectra’s of the formulation correlate with peaks of drug spectrum. This indicates that
the drug is compatible with all the formulation components. The spectra of all
formulations were shown Figure no. from 6.3-6.5.
The results of IR spectral analysis showed the following major peaks for DCL,
chitosan and their formulation components are tabulated in the table no.6.2.
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Figure No.6.3: Fourier Transform Infrared Spectroscopy (FT-IR) of Doxycycline.
Figure No. 6.4: Fourier Transform Infrared Spectroscopy (FT-IR) Of Chitosan.
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Figure No.6.5: Fourier Transform Infrared Spectroscopy (FT-IR) of formulation.
Fourier Transform Infrared Spectroscopy:-
The peaks of formulation were compared with the peaks of the drug and we found the
maximum similarities. Finally we conclude that the drug retains its originality even
after formulation, so the drug may not get disturbed in the formulation.
Table No.6.2: Data of the FT-IR Spectra of Pure Doxycycline(DCL) and Polymer
Chitosan Peaks of Functional Group (Cm-1).
FORM
ULATI
ON
C=O
Stretch
i-ng
cm-1
Ar-
CH
Stretc
hi-ng
cm-1
-OH
stretch-
ing
cm-1
N-H
bendi-
ng
cm-1
-OH
bendin-
g cm-1
C-N
Stretchi-
ng cm-1
C-C-C O
Stretchi-
ng cm-1
DCL 1615.65 2900 3330 1570 1460.73 1243.79 1175.32
DCL+
Chito-
san
1615.6
4 2967 3330.33 1578.06 1460.37 1243.58 1175.37
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• Differential Scanning Calorimetry:
DSC is useful in the investigation of solid state interactions. Thermograms are
generated for pure drug and physical mixtures of drug along with other excipients. In
the absence of any interaction, the thermogram of mixtures show endothermic peak
corresponding to that of  pure  drug. In the event that interaction occurs, this is
indicated in the thermogram of a mixture by  the shift in the value of melting
endotherm of the pure drug.
The DSC thermogram of pure DCL and its mixture with different excipients
are shown in figure. Pure DCL showed a sharp endotherm at 219.78C corresponding
to its melting point/transition temperature. There was no appreciable change in
endotherm peaks of formulation compared to pure drug. This observation further
supports the IR spectroscopy results, which indicated the absence of any interaction
between drug and additives used in the preparation.
Figure No.6.6: Differential Scanning Calorimetric (DSC) Thermogram of
Doxycycline Hyclate Drug.
67
Figure No.6.7: Differential Scanning Calorimetric (DSC) Thermogram of
Chitosan Polymer.
Figure No.6.8: Differential Scanning Calorimetric (DSC) Thermogram of
Formulation.
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4. Preparation of Drug Loaded Chitosan Inserts:
The optimum concentration of chitosan used for the preparation of inserts was found to
be 2% w/w, because at this concentration the  inserts were flexible and easily
removable from die, at higher conc. of polymer, the polymer dispersion was highly
viscous and difficult to filter using muslin cloth, inserts were brittle and difficult to
remove from die.
The amount of drug added to polymer solution changes the inserts characteristics an
optimum conc. of drug to be loaded was found to be less than 30% w/w to polymer, at
higher drug conc. (i.e. >30%) the inserts were stiff and brittle. Plasticizer was not used
because inserts obtained were flexible with plain chitosan. There was no visible sign of
crystallization.
5. Evaluation of Physical Parameters of DCL Loaded Chitosan Inserts:
a) Physical appearance:
Both drug and polymer combination used for formulation of periodontal inserts
showed good film properties and reproducibility. The fabricated inserts were thin,
flexible, elastic, smooth and non transparent.
Photography of doxycycline hyclate was shown in the figure no.6.6.
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Figure No.6.8: Photograph Showing Doxycycline Hyclate Periodontal Inserts.
1) Plain Chitosan Insert 2) Single Layer With 10% of DCL
3) Single Layer With 20% of DCL 4) Single Layer With 30% of DCL
5) Bilayer Layer With 30% of DCL 6) Trilayer Layer With 30% of DCL
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b) Thickness Measurement:
Thickness of each insert was measured at six different points and average thickness
with standard deviation was calculated. The thickness of the various inserts as given
in the table no.6.3. The data of inserts thickness indicates that there was no much
difference in the thickness within the formulation. The thickness of the inserts was
increased as increased in the drug concentration and more thickness was obtained in
bilayer and trilayer respectively.
c) Weight variation test:
Drug loaded inserts (2X7) were test for uniformity of weight, the results of weight
uniformity are given in the table no.6.3 with less standard deviation values which
indicates that  the inserts were uniform in  weight. The data of weight uniformity
indicates that as the concentration of the drug increases there is an increase in the
weight of the insert. This is an agreement with uniformity of thickness of the film as
shown in the table no.6.3.
d) Folding endurance:
Table no.6.3. Shows the value of folding endurance. There replication of each test was
carried out. It was found that folding endurance of the inserts was decreased by
increase  in the drug concentration. Bilayer and trilayer inserts exhibits minimum
folding endurance as compared to the other inserts. It is evident from the literature that
the films having folding endurance having more than 100-150 is considered as
optimum. In the present study the folding endurance was reduced in all inserts upon
the increase in concentration of drug and also formulating into bilayer and trilayer
inserts. However, the folding endurance of the bilayer and trilayer inserts containing
30% drug was also more than 150. Therefore the inserts of the study were having very
good folding endurance and can be considered as optimum.
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Table No. 6.3: Data of Physical Measurement values of Doxycycline Inserts.
Insert
Code
Thickness
( mm)AM ± SD
Folding
Endurance
Weight
Uniformity
(mg)
CP 0.103±0.0157 340±2.581989 0.8±0.208167
DSL-10% 0.124 ±0.049 280±14.719 1.0± 0.208
DSL-20% 0.171 ±0.278 260.75±13.50 1.5 ±0.346
DSL-30% 0.197 ±0.024 201.75±19.431 2.2 ±0.057
DBL-30% 0.360 ±0.010 187±9.128 2.9 ±0.30
DTL-30% 0.456±0.0030 155.25±9.844 3.9 ±0.888
e) Percentage Moisture Loss:
This test is of great significance as variation in moisture content causes a significant
variation in mechanical properties of the inserts especially when inserts comprises of
hygroscopic components. Moisture loss studies were conducted on various
formulations and reported in the Table no.6.3. It was observed  that formulations
containing maximum amount of drug showed maximum amount of moisture loss
because of more concentration of drug which undergoing moisture loss in dry
condition.
72
Table No.6.4: Data for Percentage Moisture Loss of Doxycycline Inserts.
INSERT CODE MOISTURE LOSS
(%) AM ± SD
CP 24.155±7.35
DSL-10% 24.77 ±12.365
DSL-20% 25.318±12.744
DSL-30% 25.37± 6.4593
DBL-30% 31.498±12.879
DTL-30% 40.43±11.737
Figure No.6.9: Graph for Percentage Moisture Loss of Doxycycline Inserts.
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f) Percentage Moisture Absorption:
This test is of great significance as variation in moisture content causes a significant
variation in mechanical properties of the inserts especially when inserts comprises of
hygroscopic components. The capacity of the inserts to take up water is an important
intrinsic parameter of the polymeric system in consideration to the release of drug.
The data are given in the Table no. 6.4.
Table No.6.5: Data for Percentage Moisture Absorption of Doxycycline Inserts.
INSERT CODE MOISTURE ADSORPTION
(%) AM ± SD
CP 28.35± 16.02
DSL-10% 28.43±5.533
DSL-20% 32.048±20.18
DSL-30% 32.526±5.501
DBL-30% 38.393±11.366
DTL-30% 40.97 ±13.625
Figure No.6.10: Graph for Percentage Moisture Absorption of Doxycycline
Inserts.
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g) Water Uptake and Swelling Behavior:
Water uptake and swelling behavior studies were conducted on formulated inserts.
Water uptake was found to be maximum with bilayer and trilayer inserts this may be
due to the presences of more concentration of chitosan. The results are showed in the
table no. After complete hydration, moderate swelling of the polymer were observed
and there is a slight increase in the diameter of inserts.
Table No.6.6: Data for Swelling Index of Doxycycline Inserts.
INSERT CODE WATER UPTAKE AND SWELLING
BEHAVIOUR
INITIAL WEIGHT
(mg) (0hr)
FINAL WEIGHT (mg)
(2hrs)
CP 4.3 4.6
DSL-10 4.7 6.3
DSL-20 4.1 4.8
DSL-30 3.5 5.8
DBL-30 4.5 4.7
DTL-30 5.1 7.4
h) Tensile Strength :
The tensile strength was determined using universal testing tensile machine for both
drug loaded and unloaded inserts. The result are given in the table no.6.7. The tensile
strength of drug loaded inserts was higher than dummy inserts. This is because of
dissolved drug strengthen the bounding of polymer chain.
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Table No.6.7: Data for Tensile Strength of Doxycycline Insert.
INSERTS
CODE
TENSILE STRENGTH
(Kg/sq.mm.)
AM ± SD
CP 1.45± 0.054
DSL-10 2.140±0.110
DSL-20 2.318±0.185
DSL-30 2.810±0.060
DBL-30 3.170±0.102
DTL-30 4.533±0.200
*Each value was an average of three determinations.
Figure No.6.11: Graph for Tensile Strength of Doxycycline Inserts.
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i) Drug Content Uniformity:
The drug content uniformity test is commonly employed for unit dose form in order to
make sure about the uniform dispersion of drug in the inserts. The drugs content value
of prepared inserts contains doxycycline hyclate were reported in the table no.6.8. The
drug loading varied from 80-98 % depending on initial drug concentration and type of
formulation.
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Table No.6.8: Data of Drug Content Uniformity of Doxycycline Insert.
Inserts Code Drug Content* (µg) Theoretical
Drug Loading
(µg)
% Drug
Loading
CS ---- ---- ---
DSL-10 107.810± 0.054 109.300 98.63
DSL-20 216.562± 0.089 218.250 99.00
DSL-30 274.062± 0.071 328.125 83.523
DBL-30 273.135± 0.064 328.125 83.241
DTL-30 272.279± 0.022 328.125 82.980
j) In-vitro Drug Release:
Since the pH of gingival fluid is between 6.5 to 6.8, phosphate 6.6 pH was used on
stimulated gingival fluid for dissolution studies. Since, the inserts remain immobile in
the periodontal pocket as static dissolution model was adopted in this work.
Release of DCL from Chitosan Inserts:
The release data of doxycycline hyclate are given in the table no.6.9, 6.10, and 6.11.
The release studies were conducted for 8 days for single layer which containing
different concentration of drug. The release time profiles from these inserts were
shown in figures. From the results it was found that there was rapid initial release of
drug on day 1 and there was a marked reduction in release from day 3 onwards and
the release was controlled and extended up to 8 days.
The cumulative percentage drug release was 96.83%, 91.009 % and 92.210 % from
inserts containing 10%, 20% and 30% of drug from single layer respectively.
A Persuval of figure no.6.12. indicated that initial rapid release must be due to burst
release effect. Burst release is due to elution of drug from the outer surface and cut
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edges of the matrix. Once the burst was completed (2days), drug was more sustained
up to 8 days. Based on the results single layer inserts of 30% drug concentration was
chosen for bilayer and trilayer studies respectively. These studies became essential in
order to control the burst effect and release for more number of days.
Release of Doxycycline Hyclate from Bilayer and Trilayer:
The release data of bilayer and trilayer 30% DCL are given in the table no.6.12 and
6.13. The release time profile from bilayer and trilayer are showed in figure no.6.12.
The bilayer and trilayer inserts showed a decreased initial burst release by more than
40%. The drug release was controlled and extended up to 13 days in case of bilayer
where as 17 days in case of trilayer respectively.
The cumulative % release of drug from single layer insert was about 90-95% on the
8th day. However the release of drug from bilayer and trilayer insert was about 90%
on 13th and 17th day. Hence, it might be informed that developing bilayer and trilayer
helped in sustaining the release for more number of days for local long term treatment
for periodontitis.
Table No.6.9: Static Dissolution-Time Profile for Chitosan Inserts Containing
Doxycyline-10%.
Time
(days)
Absor
bance*
Dilution
factor
Conc. of
drug
released (µg)
AM ± SD
Cumulative
release (µg)
% conc.
of drug
released
‘a’
% conc.
of drug
unreleas
ed
01 0.405 5 61.562 61.562 57.1023 42.897
02 0.135 5 19.375 80.937 75.073 24.927
03 0.074 5 9.843 90.780 84.136 15.864
04 0.052 5 6.406 97.186 90.1456 94.059
05 0.025 5 2.187 99.373 92.1741 7.8257
06 0.024 5 2.031 101.404 94.0580 5.942
07 0.027 5 2.343 103.747 96.231 3.769
08 0.018 3 0.656 104.403 96.839 3.161
• Each value is an average of three replication, Medium - Phosphate buffer 6.6 pH.
• Static dissolution conditions are: Temperature=37° C
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Table No.6.10: Static Dissolution-Time Profile for Chitosan Inserts Containing
Doxycyline-20%.
Time
(days)
Absorb
ance*
Dilution
factor
Conc. of
drug
released
(µg)
AM ± SD
Cumulative
release (µg)
% conc.
of drug
released
‘a’
% conc. of
drug
unreleased
01 0.350 10 105.937 105.937 48.917 51.083
02 0.417 5 63.437 169.374 78.2103 21.789
03 0.103 5 14.375 183.749 84.848 15.152
04 0.042 5 4.843 188.592 87.0845 12.916
05 0.031 5 3.125 191.717 88.527 11.473
06 0.028 5 2.656 194.373 89.7539 10.247
07 0.030 3 1.781 196.154 90.576 9.424
08 0.021 3 0.937 197.091 91.009 8.991
• Each value is an average of three replication*
• Static dissolution conditions are: Temperature=37° C
• Medium = Phosphate buffer, pH 6.6 (l ml).
Table No.6.11: Static Dissolution-Time Profile for Chitosan Inserts Containing
Doxycyline-30%.
Time
(days)
Absor
bance
Dilution
factor
Conc. of
drug
released (µg)
AM ± SD
Cumulative
release (µg)
% conc.
of drug
released
‘a’
% conc. of
drug
unreleased
01 0.499 10 152.50 152.50 55.644 44.356
02 0.453 5 69.062 221.562 80.843 19.157
03 0.125 5 17.812 239.374 87.343 12.657
04 0.058 5 7.343 246.717 90.022 9.978
05 0.025 5 2.187 248.904 90.820 9.180
06 0.022 5 1.718 250.622 91.447 8.553
07 0.019 5 1.25 251.872 91.903 8.097
08 0.020 3 0.843 252.715 92.210 7.790
• Each value is an average of three replication*
• Static dissolution conditions are: Temperature=37° C
• Medium = Phosphate buffer, pH 6.6 (l ml).
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Table No.6.12: Static Dissolution-Time Profile for Chitosan Bilayer Inserts
Containing Doxycyline-30%.
Time
(days)
Absorb
ance*
Dilution
factor
Conc. of
drug
released
(µg)
AM ± SD
Cumulative
release (µg)
% conc.
of drug
released
‘a’
% conc. of
drug
unrelease
d
01 0.469 10 143.125 143.125 52.400 47.600
02 0.365 5 55.312 198.437 72.651 27.349
03 0.166 5 24.218 222.655 81.518 18.482
04 0.068 5 8.906 231.561 84.778 15.222
05 0.039 5 4.375 235.936 86.380 13.620
06 0.030 5 2.968 238.904 87.467 12.533
07 0.025 5 2.187 241.091 88.268 11.732
08 0.033 3 2.062 243.153 89.023 10.977
09 0.030 3 1.781 244.934 89.675 10.325
10 0.029 3 1.6875 246.621 90.292 9.708
11 0.023 3 1.125 247.746 90.704 9.296
12 0.020 3 0.843 248.589 91.013 8.987
13 0.018 3 0.656 249.245 91.253 8.747
• Each value is an average of three replication*
• Static dissolution conditions are: Temperature = 37° C
• Medium = Phosphate buffer, pH 6.6 (1 ml).
80
Table No.6.13: Static Dissolution-Time Profile for Chitosan Tri Layer Inserts
Containing Doxycyline-30%.
Time
(days)
Absorb
ance*
Dilution
factor
Conc. of drug
released (µg)
AM ± SD
Cumulative
release (µg)
% conc.
of drug
released
‘a’
% conc.
of drug
unreleas
ed
01 0.363 10 110.00 110.00 40.399 59.601
02 0.375 5 56.875 166.875 61.288 38.717
03 0.165 5 24.062 190.937 70.125 29.874
04 0.130 5 18.593 209.53 76.954 23.045
05 0.069 5 9.0625 218.592 80.282 19.717
06 0.043 5 5.000 223.592 82.118 17.881
07 0.035 5 3.750 227.342 83.495 16.504
08 0.027 5 2.500 229.842 84.414 15.585
09 0.025 5 2.187 232.029 85.217 14.783
10 0.023 5 1.875 233.904 85.906 14.093
11 0.027 3 1.500 235.404 86.456 13.543
12 0.025 3 1.312 236.716 86.938 13.061
13 0.023 3 1.125 237.841 87.351 12.648
14 0.021 3 0.937 238.778 87.696 12.303
15 0.019 3 0.750 239.483 87.955 12.044
16 0.017 3 0.562 240.045 87.996 12.003
17 0.015 3 0.375 240.420 88.299 11.700
• Each value is an average of three replication*
• Static dissolution conditions are: Temperature = 37° C,
• Medium = Phosphate buffer, pH 6.6 (1 ml).
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Figure No.6.12: Cumulative Percentage Release of Doxycycline Hyclate from
Chitosan Inserts.
6.     RELEASE KINETICS:
The release data of doxycycline hyclate was proposed to understand the linear
relationship. The data was proposed for reggration analysis.
Release Mechanism:
Since the drug loaded chitosan inserts were intact during static dissolution studies,
dissolution rate control release was ruled out. Hence data was fit according to higuchi
ficks modle.
A Persuval of figure indicated that linear relationship was observed from 3rd to 8th day
in case of single layer and 3rd to 13th day and 17th day in case of bilayer and trilarer
respectively. The apperances of straight line indicates the release of drug from
prepared inserts were diffusion rate control.
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DEPENDENT-MODEL METHOD (KINETIC MODELING)
The results obtaining in vitro release studies were plotted in different models of data
Treatment as follows:
 ZERO ORDER
 FIRST ORDER
 HIGUCHI EQUATION
 KORSEMEYER PEPPAS EQUATION
FIRST ORDER:-
Log of % Cumulative Drug Release VS. Time
Best Fit line for first order equation for chitosan inserts containing doxycycline.
Formulations are (DSL-10%, DSL-20%, DSL- 30%, DBL-30% and DTL-30%).
Figure No.6.13: First Order Equation for Chitosan Inserts Containing
Doxycycline hyclate
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HIGUCHI EQUATION:-
% Cumulative Drug Release Vs. Square Root of Time
Best Fit line for Higuchi equation for chitosan inserts containing doxycycline.
Formulations are (DSL-10%, DSL-20%, DSL- 30%, DBL-30% and DTL-30%)
Figure No.6.14: Higuchi Equation for Chitosan Inserts Containing Doxycycline
hyclate
KORSEMEYER PEPPAS EQUATION:-
Log of % Cumulative Drug Release Vs. Log Of Time
Best Fit line for Korsemeyer Peppas equation for chitosan inserts containing
doxycycline. Formulations are (DSL-10%, DSL-20%, DSL- 30%,DBL-30% and
DTL-30%) .
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Figure No.6.15: Korsemeyer Peppas Equation For Chitosan Inserts Containing
doxycycline hyclate.
The results obtaining by In-vitro release studies were plotted in different kinetic
models as follows.
Table No.6.14: Data of Kinetic modeling of Doxycycline Inserts.
INSERT
CODE
ZERO ORDER FIRST
ORDER
HUGUCHI
MATRIX
KORSEMEYER
PEPPAS
R² R² R² R² N
DSL-10 0.559 0.952 0.887 0.415 0.937
DSL-20 0.596 0.806 0.847 0.422 0785
DSL-30 0.559 0.766 0.823 0.402 0.789
DBL-30 0.479 0.743 0.738 0.388 0.811
DTL-30 0.513 0.750 0.764 0.421 0.822
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k) In-Vitro Antibacterial Activity:
Table no. 6.15. Shows more in-vitro antibacterial activity against S. mutans was found
on day1 with all single layer inserts. Whereas with bilayer and trilayer less activity
was observed on day 1. From the study it was conformed that bilayer and trilayer
inserts exhibited antibacterial activity for a long period in comparison to single layer.
This may be due to sustained release of drug from bilayer and trilayer inserts. The
zone of inhibition values of DCL shown in figure no.6.16.
Table No.6.15: In vitro antibacterial activity data of Doxycycline hyclate.
Days Diameter of inhibition of growth area of S.mutans (mm)
DSL-10 DSL-20 DsL-30 DBL-30 DTL-30
1 16 20 26 23 20
2 14 17 22 18 17
4 10 13 16 14 13
8 7 10 11 12 11
11
-
- - 10 9
14
-
- - 9 7
17
-
- - 7 5
Figure No.6.16: Zone of inhibition of Doxycycline Hyclate.
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L) Stability Study:
All the polymeric inserts were obsersved for physical change, color, appearance and
drug content. Stability data at different temperature and humidity condition revelaed
on physical appearances and uniformity in drug content. The drug remained intact and
stable  in the  polymer on storage for 3 months. The results obtained from these
methods and the discussion of the obtained results is given in the following tables.
Table No.6.16: Data for Physical appearance of Drug Stability Study.
TIME
IN
DAYS
DSL-10 DSL-20 DSL-30 DBL-30 DTL-30
0 No change
30 No change
60 No change
90 Yellow to brown
Table No.6.17: Stability Studies for Drug Content at various temperatures for
Chitosan Inserts Containing Doxycycline Hyclate.
Insert code Initial drug
conc. (µg)
30 Days 60 Days 90 Days
A.F A.F A.F
DSL10 107.810 107.800 107.783 107.700
DSL-20 216.562 216.560 216.534 216.487
DSL-30 274.062 274.058 274.022 273.987
DBL-30 273.135 273.130 273.102 273.029
DTL-30 272.279 273.274 273.250 273.147
Each value is an average of 3 determinations.
A.F = Packed in aluminum foil.
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The inserts were also observed for their appearance, texture and drug content
uniformity.   These properties did not change in all the inserts during the period of
study. Hence, prepared formulations have a good stability.
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9.SUMMMARY
Periodontitis is the disease, which is caused by specific microorganism in
periodontal pockets and led to an increased interest in and usage of antibacterial agent
in periodontal therapy.
The problems of administering drugs systemically, such as adverse reaction,
have focused attention on ways of applying the drug directly to its target site.
The use of drugs to treat plaque associated periodontal diseases is an attractive
prospect, since conventional treatment can be demanding on both patient and operator.
So there is much interest in developing alternative strategies.
Number of drug delivery system has been investigated for administration of
antibacterial / antimicrobial agents into periodontal pocket for local action in the
treatment of periodontitis.
Device placed into periodontal pocket can produce a local drug concentration
100 times higher than achievable systemically and importantly reduces the total patient
dose by over 400 fold.
For developing the local drug delivery system, as it was proved antimicrobial agent is
effective against wide range of oral pathogens.
Mucoadhasive dosage form utilizes the mechanism of bioadhesion and
produces an  intimate contact  with the biological  membrane.  Hence, chitosan was
selected as a biodegradable polymer for the development of drug delivery device
which stays for longer time at the site of action
The inserts of chitosan polymer (biodegradable) 2% w/v were prepared by
solvent casting method using 1% v/v acetic acid as a casting solvent. In the present
work chitosan inserts containing doxycycline hyclate were prepared in three different
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percentages (10%, 20% and 30%) to the weight of polymer .Bilayer and trilayer inserts
also were prepared for preventing initial burst release.
Microscopical feature revealed that the drug was dissolved in the polymer
matrix rather than dispersining. The average weight of single layer inserts range from
0.8 to 2.2 mg and average weight of bilayer and trilayer ranges from 2.9 to 3.9 mg. The
thickness of the insets ranges from 0.103±0.015 mm to 0.456±0.0030 mm. There was
no significant difference in the thickness among the different inserts since the drug
was dissolved in the polymer matrix. The tensile strength of the inserts range from
1.45 ± 0.054 kg to 4.533 ± 0.200 kg. Tensile strength is minimum for plain inserts and
maximum for inserts containing 30% drug. The data obtained revealed that
incorporation of drug increases the physical strength of the inserts, however this may
not cause any problem during their clinical application. The folding endurance studies
showed that plain inserts exhibited maximum folding endurance followed by drug
loaded inserts respectively.
In vitro dissolution rate studies were carried out by static dissolution method
for inserts for a period of 8, 13 and 17 days respectively. This showed a burst release
initially followed by a progressive fall in the release of the drug. The inserts DSL-10,
DSL-20 and DSL- 30 showed 96.839%, 91.009 % and 92.210% respectively at the
end of 8 days. The bilayer insert (DBL-30) showed 91.253% at the end of 13. The
trilayer insert (DTL-30) showed 88.299 % respectively at the end of 17days of static
dissolution period. Initial burst effect was reduced once the chitosan strips were
formulated in multilayer form and also release of drug was extended and controlled
up to 17 days. The plots of the cumulative amount of drug release per unit surface
area against sq. root of time, confirms to Higuchi’s diffusion model i.e., the release
kinetics of doxycycline from chitosan strips followed first order. The initial burst
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release is essential to achieve high concentration of drug in gingival sulcus. This is a
primary objective of the periodontal therapy.
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10.CONCLUSIONS
From the obtained results, it can be concluded that
 Novel multilayer inserts of doxycycline hyclate can be formulated by solvent
casting method technique.
 Evaluation parameters like thickness, tensile strength and folding endurance
indicates that inserts were mechanically stable in all the inserts formulations.
 Percentage weight variation and drug content uniformity found to be uniform in all
the formulations.
 The FT-IR and DSC spectra revealed that, there was no interaction between
polymer and drug. Hence, Polymer used was compatible with the drug.
 In-vitro drug release showed an abrupt release in the first day in single layer
whereas this initial burst release was controlled by formulating in to bilayer and
trilayer which was controlled the release uniformity in a specified period of time.
 In-vitro antibacterial activity showed good correlation with respective in-vitro
drug release. Release kinetics from all the inserts follows diffusion rate controlled
mechanism.
 All the inserts were found to be stable over the storage period of 90 days and
condition tested.
 From this study it can be concluded that bilayer and trilayer were developed which
can be delivered drug up to 13 and 17 days respectively.
 Future scope:-
 Addressing the final multilayer formulation needs considerable amount of study.
 In-vivo evaluation study of multilayer inserts of DCL and establishment of in-vitro
and in-vivo correlation.
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11.INTRODUCTION
Periodontal diseases are recognized as the major public health problem throughout the
world. Daily oral hygiene plays a vital role in maintaining healthy teeth and gums.
Periodontal disease can do occur in all age groups, ethnicities, races, genders and
socioeconomic levels.
The term “Periodontal Disease” broadly defines several diseases associated
with the periodontium. Changes in the microflora, histopathological variations,
clinical symptoms, and the location of the inflammation help to further delineate
periodontal disease. Gingivitis, the moderate stage of the disease, caused by an
accumulation of supragingival plaque is characterized by swelling, light bleeding and
redness of marginal gingiva. Gingivitis is associated with a change in microflora,
shifting from a grampositive anaerobic flora to a more gram-negative flora.
Periodontitis a more severe stage of periodontal disease, results in the resorption of
the alveolar bone and detachment of the periodontal ligaments supporting the tooth.
Figure No.1.1: Comparision of Healthy Periodontum/Gums and Periodontal
Disease.
2One of the clinical features of the periodontal disease is the formation of periodontal
pocket, which is pathologically deepened sulcus. In normal sulcus, the gap between
the gingiva and the tooth is normally between 1 and 3 mm deep. However, during
periodontitis, the depth of pocket usually exceeds 5mm1.
Causes of Periodontal Diseases:
The main cause of periodontal disease is bacteria plaque, a sticky, colorless film that
constantly forms on teeth. However, factors like smoking/ tobacco use, genetics,
pregnancy and puberty, stress, medication, clenching or grinding teeth, diabetes and
poor nutrition also lead to periodontal diseases. Plaque (more plaque formation)
Gingival inflammation Pocket formation Periodontal pathogens grow only where
atmosphere and nutrient composition are strictly conductive to their requirements and
the disease once established, causes major changes in the periodontal
microenvironment. The gingival crevicular fluid (GCF) flow occurs at extremely low
levels in healthy gingival sulci but increases enormously to 3.5ml/day or more. The
most commonly grown anaerobic pathogenic bacteria are Actinobacillus
actinomycetencomitans, Bacteroides gingivalis, Bacteroides melaninogenicus sub
species intermedius, Porphyromonas gingivalis and Prevotella intermedia. Clinical
signs such as bluish red thickened marginal gingiva, bluish red vertical zone from the
gingival margin to the oral mucosa, gingival bleeding and localized pain are
suggestive of the presence of periodontal pockets 2, 3.
Overview of the Pathogenesis of Periodontal Disease:
The normal healthy gingiva is characterized by its pink color, its firm consistency and
free from histological evidence of inflammation, but this ideal condition is very rarely
seen in microscopic tissue sections. This is because most human gingival tissues are,
no matter how clinically healthy in appearance, slightly inflamed due to constant
3presence of microbial plaque. Even in healthy state, the gingiva has a leukocyte
infiltrate that is predominantly comprised of neutrophils or polymorphonuclear
leukocytes. These leukocytes rephagocytose whose primary purpose is to kill bacteria
in the gingival crevicular area or the gingival pocket. Neutrophils are recruited to the
periodontal pocket or the gingival crevice because of attracting molecules, released by
bacteria, called chemtactic peptides. Furthermore, as bacteria damage the epithelial
cells, they cause epithelial cells to release molecules termed cytokines that further
attract leukocytes to the crevice. The neutrophilscan phagocytose and digest bacteria
within crevice and therefore remove these bacteria from the pocket. If the neutrophil
becomes overloaded with bacteria, it degranulates or explodes. This causes tissue
damage from toxic enzymes that are released from the neutrophils. Therefore,
neutrophils can be viewed as being both helpful and potentially harmful. Depending
on the  individual, progression from gingivitis to periodontitis requires varying
amounts of time. But in normal situation, more than 6 months may be needed for the
lesion of gingivitis to change to periodontitis 4, 5, 6.
Microbiology of Periodontal Disease:
About 300 or  400 bacterial species are found in the  human subgingival plaque
samples. Of that number, possibly 10-20 species may play a role in the pathogenesis
of destructive periodontal disease. These bacterial species must be able to colonize in
order to survive and damage the periodontal tissues. To colonize subgingival sites,
microbes must be able to,
1) Attach to periodontal tissues
2) Multiply
3) Compete with other microbes in their habitat and
44) Defend themselves from host defense mechanisms.
The gingival sulcus area is a lush place for microbial growth, but in order to colonize
a subgingival site, a bacterial species must overcome a number of host-derived
obstacles. If a species successfully enters underlying connective tissue, it faces a
multitude of host immune cells including B and T lymphocytes, neutrophils,
macrophages and lymphocytes. To be successful, bacteria must have the ability to
evade all these host response mechanisms. The microbes involved in periodontal
disease are largely gram-negative anaerobic bacilli with some anaerobic cocci and a
large quantity of anaerobic spirochetes 4, 8, 9.
Histopathological Changes:
The major pathological features of periodontitis are the accumulation of an
inflammatory infiltrate in the tissue adjacent to the periodontal pocket, breakdown of
connective tissue fibers anchoring the root to gingival connective tissue and alveolar
bone, apical migration of the epithelial attachment or junctional epithelium, and
resorption of the marginal portion of the alveolar bone resulting in eventual tooth loss.
Page & Schroeder developed a system to categorize the clinical and histopathological
stages of periodontal disease and defined four histopathological stages of periodontal
inflammatory changes.
• Health – Pristine Condition
• Initial lesion – Clinically healthy
• Early lesion – Early gingivitis
• Established lesion – Chronic gingivitis
• Advanced lesion – Chronic periodontitis
5Following histopathological description by Kinane and Lindhe is based on model
Proposed by Page & Schroeder is summarized in table below 4,7,10
Table No.1.1: Histopathological Description
Clinical
condition
Histopathological condition
1. Pristine gingiva Histological perfection
2. Normal healthy
gingiva
Initial lesion
3. Early gingivitis Early lesion
4. Established
gingivitis
Established lesion with no bone loss nor apical
epithelial migration (Plasma cell density between 10%
and 30% of leukocyte infiltrate.
5. Periodontitis Established lesion with bone loss and apical epithelial
migration from the cement enamel junction (Plasma
cell density >50%).
The initial lesion appears within 4 days of plaque accumulation, characterized by an
acute inflammatory response. The major features consist of an increased flow of
crevicular fluid; inflammatory  infiltrate occupies 5% to 10% of the gingival
connective tissue below the epithelium and loss of collagen.
After approximately 7 days of plaque accumulation, an inflammatory infiltrate of
mononuclear leukocytes develops at the site of initial lesion as it progresses to the
early lesion. At this stage, the infiltrate occupies about 15% of the gingival connective
tissue, with collagen destruction in the infiltrated area reaching 60-70%. Clinically the
inflammatory changes are visible and present as edema and erythema.
After 2 to 3 weeks of plaque accumulation, the early lesion evolves into established
6lesion, characterized by further increase in the size, predominance of plasma cells and
lymphocytes at the periphery of lesion.
Features of advanced lesion include periodontal pocket formation, surface ulceration
and suppuration, destruction of alveolar bone and periodontal ligament, tooth
periodontitis is marked by the change in T-cell to B-cell predominance.
Mobility and drifting, and eventually tooth loss. The advanced lesion characterized by
the same feature present in the established gingival lesion.
TREATMENT APPROACHES
Conventional Periodontal therapy:
The purpose of periodontal treatment is to cure the inflamed tissue, reduce the number
of pathogenic bacteria and eliminate the depth of the diseased pockets and to stop
bone resorption. The conventional methods of pocket elimination are more or less
mechanical and are aimed at removal of supra and mechanical plaque and degenerated
and necrotic tissue lining the gingival wall of periodontal pockets through scaling,
root planning and curettage11.
The mechanical debridement alone often leaves behind significant number of
pathogens due to possible instrumentation or ability of microorganism to penetrate
into deeper tissues. Inaccessibility and recolonization of pathogens can occur after
scaling and root planning. With oral hygiene, a pathogenic subgingival microbial may
reestablish within 42 - 60 days after a single periodontal debridement session13. Some
deep periodontal pockets experience putative pathogen recolonization by 120 - 240
days despite multiple sessions of subgingival instrumentation and meticulous supra
gingival plaque control12.
7Antibiotic Therapy:
The use of antibiotics in the treatment of periodontal diseases helps to reduce or
eliminate bacteria that cannot be removed by scaling and root planning.
Chemotherapeutic agents can be administered systemically or locally. Tetracycline’s,
imidazole derivatives, fluoroquinolones etc., are the most favored antibiotics.
Antimicrobials used to treat dental infections can be divided into two main categories,
i.e., broad spectrum and narrow spectrum. Narrow-spectrum antimicrobials include
penicillin, amoxicillin, cephalexin, macrolides and tetracyclines. These drugs are
having a limited antimicrobial efficacy (Table1.2), as they are not effective against
aerobic and anaerobic beta lactamase producers, as well as other specific organisms14
Systemic  periodontal antimicrobial therapy is based on the premise that specific
microorganism cause destructive periodontal disease and that the antimicrobial agent
in the periodontal pocket can exceed the concentration necessary to kill the pathogens.
Systemic antibiotics can reach microorganisms at the  base of  deep periodontal
pockets and furcation areas via serum and may also affect organisms residing within
gingival epithelial and connective tissue. With systemic antibiotic therapy there is a
considerable variability in the therapeutic activity due to factors like poor absorption
in the gastrointestinal tract, first pass metabolism, systemic distribution, bacterial
sensitivity and resistance15.
Some studies also report poor results due to the fact that the active product does not
reach in adequate concentration at the site of action, as it is not retained locally for
sufficient period of several thousand folds before it reaches the site of action
8necessitating ingestion of large doses.
The increased toxic effects of these elevated dose levels make systemic administration
unacceptable due to low benefit to risk ratio. Repeated long term use of systemic
antibiotics is fraught with potential danger including resistant strains and super
infections17.
These draw backs can be markedly reduced if antimicrobial agent to be used locally.
Because of the smaller dosage used and topical chemotherapy is much safer than
systemic chemotherapy in avoiding the side effects of antibacterial agents16
Local Drug Delivery:
Local applications (as mouth rinse, gels, tooth paste etc,) control only supra gingival
microbial plaque or periodontal disease involving pocket formation and also requires
high initial concentrations and multiple applications in order to provide sustained
effectiveness18.
Local application of antibiotics has been achieved either by subgingival irrigation
or by incorporating the drug into different devices for insertion into periodontal
pockets. Many drugs like chlorhexidine, tetracycline are tried as mouth rinses in the
treatment of periodontal diseases. In-spite of its superior effects, chlorhexidine does
not reach the periodontal pocket when administered as mouth rinse. Subgingival
irrigation of antimicrobial involves local drug delivery but not controlled release.
Local drug delivery devices are of two types. In the first type, the drug delivery
system is designed to deliver agent locally in the periodontal pocket but without any
mechanism to retain therapeutic levels for a prolonged period of time. Such device
generally exhibits exponential increase and decrease in drug concentration at the
9site19.
Second type is the controlled release local drug delivery devices which may secure
antimicrobial effect for a prolonged period of time at the diseased site, than that can
be achieved by systemic or local topical applications and also by passes the systemic
complications20.
The controlled release delivery of antimicrobials directly into periodontal pocket has
received greatest interest and appears to hold some promise in periodontal therapy.
These delivery systems are produced by immobilizing antibiotic and antimicrobial
agents with a carrier substance to provide controlled local release.
Local antimicrobial therapy in periodontitis involve direct placement of antimicrobial
agents into subgingival sites minimizing the impact of the agents on non oral body
sites. Local antimicrobial agents may be personally applied as a part of home care oral
hygiene regimens and/or professionally applied as part of clinic based treatment
procedures. Local antimicrobial therapy in periodontitis may be further classified as
providing either non-sustained or sustained subgingival drug delivery. Non-sustained
subgingival drug delivery provides high pocket concentrations of the antimicrobial
agent over an extended time period within  periodontal pockets. Controlled drug
release can be  provided with subgingival irrigation of an agent intrinsically
substantive for both tooth surfaces or pocket placement of commercial antimicrobial
fibers, gel or films. The potential application of these new concepts to periodontology
and the treatment of periodontal infections was championed and developed into a
viable concept primarily by Dr. J. Max Goodson24.
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Table 1.2:- Susceptibility of infective microorganisms to the major
antimicrobials.
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1
Mac
olid
es
Clin
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myci
n
Metro
nidazo
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Tetra
cyclin
e
Levo
floxa
cin
Gati
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Aerobic
bacteria
Streptococc
-us Group A + + + + + + 0 A+ + +
Streptococc
-us spp + + + + + + 0 + + +
Staphylococ
-cus spp 0 + + + + + 0 A+ A+ +
Capnocytop
-haa spp + + + A+ A+ + 0 + + +
Eikenella
spp + 0 + 0 A+ 0 0 + + +
Anaerobic
bacteria
Peptostrepto
-coccus spp + + + + + + A+ A+ A+ +
Actinomyce
-s spp + + + + + + + A+ + +
Prevotella
spp + A+ + 0 0 + + A+ A+ A+
Porphyromo
-ns spp
A
+
A+ + 0 0 + + A+ 0 A+
Fusobaceriu
-m spp
A
+
A+ + 0 A+ + + A+ 0 A+
Bacteoride A
+
A+ + 0 0 + + A± 0 A±
A +: Higher activity towards organisms
+: Moderate activity
0: No activity
Cef/1 – first generation cephalosporins
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LOCAL ANTIMICROBIAL AGENT POCKET DELIVERY
Advantages of Local Controlled Release Devices:
• It is useful in controlling and monitoring the desired drug levels in the site.
• It allows local modification of tissue permeability inhibit protease activity or
decrease immunogenic response.
• It is a useful means of delivery of drug to the oral cavity that is not absorbed into
the gastro intestinal system (e.g. chlorhexidine).
• It bypasses hepatic first pass metabolism, therapy offering a greater bioavailability
and reduction in dosage21.
• The drug escapes the acidic environment of the stomach.
• Therapeutic serum concentrations of the drug can be achieved more rapidly
• Sustained release drugs offer a onetime application has an advantage over repeated
application.
Disadvantages:
• There is difficulty in placing therapeutic concentrations of antimicrobial agent into
deeper parts of periodontal pockets and frication lesions.
• Personal application of antimicrobial agent by patient’s lack of adequate manual
dexterity, limited understanding of periodontal anatomy and poor compliance and
performance with recommended procedures.
• The task of professionally applying local antimicrobial agent in periodontitis
patients with numerous advanced lesions distributed throughout their mouth is time
consuming and labor intensive.
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• Antimicrobial agents locally applied into periodontal pockets do not markedly
affect periodontal pathogens residing within adjacent gingival connective tissues
and on extra-pocket oral surfaces, which increases the risk of later reinfection and
disease recurrence in treated areas.
Success of any drug system designed to target periodontal infection depends upon its
ability to deliver the anti-microbial agent to the base of pocket at a bacteriostatic or
bactericidal concentration. It must also facilitate retention of medicament long enough
to ensure an efficacious result. Commonly used techniques22 to administer
antimicrobial with regard to attaining these criteria are compared in Table 1. 3.
TableNo.1.3: Comparison of Drug Delivery Systems for Management of
Periodontitis.
Mouth
Rinse
Subgingival
Irrigation
Systemic
delivery
Controlled
delivery
Reaches site of
disease and activity Poor Good Good Good
Adequate drug
concentration Good Good Fair Good
Adequate duration
of therapy Poor Poor Fair Good
Local antimicrobial therapy in periodontitis involves direct placement of an
antimicrobial agent(s) in to subgingival sites, minimizing the impact of the agent(s)
on non oral body sites.
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Types Of Local Antimicrobial Agent Therapy In Periodontal Diseases
Include.
1. Personally applied (in-patient home self care)
• Non-sustained subgingival drug delivery (home oral irrigation)
• Sustained subgingival drug delivery (Not developed to date)
2. Professionally applied (in dental office)
• Non sustained subgingival drug delivery (Professional pocket irrigation)
• Sustained subgingival drug delivery (Controlled release devices)
Controlled drug delivery systems are designed to deliver the drug slowly for
prolonged periods for sustaining drug action. These dosage forms are commonly
referred as sustained-release, controlled-release, timed-release and slow release.
These technologies assure therapeutic concentrations of the antimicrobial agents in
the subgingival area, at least for 3 days following  a single application. Most
controlled release  devices for periodontal application are  polymer based, with
diffusion of drugs across a rate controlling membrane.
CONTROLLED RELEASE LOCAL DELIVERY DEVICES
These devices employ the controlled release technologies to assure therapeutic
concentrations of  the antimicrobial in the  sub gingival area for at least 3 days
following a single application.
Different Types of Controlled Release Local Delivery Devices Fall Into
Following Groups
Reservoir devices (membrane diffusion systems)
This includes dialysis tubing 3-5 mm long, 0.2 mm wide containing a core of drug
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solution. This is left in the pocket for a week. Reservoir devices that lack rate control
include hollow fibers, gels and dialysis tubing. These systems tend to release
chemotherapeutic agents very  quickly and only marginally qualify as sustained
release devices. The problems associated with these devices are, irritation of the
pocket, premature loss from the pocket and rapid drug release23.
Monolithic devices
Bio absorbable, biodegradable materials can be left in situ. This eliminates the risk of
disturbing a site after therapy. The controlled release local delivery devices
(monolithic) are usually polymers (films/fibers) containing homogeneously dissolved
or dispersed drug.
In these devices, the drug is dispersed in a solid polymer matrix, Examples include
acrylic strips and ethylene vinyl acetate (EVA) fibers. Acrylic strips are typically 0-2
mm thick. Treatment is carried out over 2 - 4 weeks, with a replacement of new strips
inserted each week. Drug release occurs over a period of 10 - 14 days. Strips tend to
be lost from the pocket. This can be avoided by applying periodontal dressing. Other
monolithic devices include strips made of ethyl cellulose (EC), poly ethylene glycol
(PEG), Hydroxy propyl methyl cellulose (HPMC) and cross linked collagen films23.
The two basic types are:
1. Fixed monolithic devices: Where the polymer maintains its integrity as the drug is
lost.
2. Erodible monolithic devices: Which breaks up as the drug is released.
If the drug is present as dispersion, the release will be proportional to the square root
of time and if the drug is present only dissolved in the constant release rates, then
decay exponentially. It is possible to obtain more constant release rates by increasing
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the concentration of drug towards the center of the monolithic core to produce a
laminated device. The various polymers used for the monolithic device are ethylene
vinyl acetate co-polymer, ethyl cellulose, methyl methacrylate, poly ethylene-2
hydroxy ethyl methylacrylate, poly (ortho esters), atellocollagen etc.
The device should be designed for rapid insertion and to minimize the pain and
discomfort to the patient. The monolithic devices can be prepared conveniently by
using simple polymer fabrication techniques.
Melt fabrication Technique
Films can be produced by extrusion in to  thin film. Another process known as
calendaring, where the polymer is squeezed between heated rollers to form film23.
Solution casting
The polymer is dissolved in a suitable solvent to form a viscous solution, which is
then spread on flat non-adhesive surface and the solvent is allowed to evaporate. The
resultant film is peeled from the surface.
Polymerization In situ
A liquid polymer or pre polymerized inside a suitable mould. The release from
monolithic devices depends on diffusion of drug through matrix. By manipulating the
system, selecting the ideal polymer, adjusting the cross-linking, fillers, plasticizers
and by using co-polymers, release of some low molecular drug can be achieved.For
an antimicrobial agent to be successful the pathogen must be known, it must be
susceptible to the drug. It should not readily develop resistance for an adequate period
of time. Also the drug should have little or no side effects 24.
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MECHANISMS OF DRUG RELEASE
The release of drug from a localized drug delivery system can be achieved by the
following mechanisms.
1. Pure diffusion
2. Chemical reactions
3. Counter-current diffusion
4. Externally imposed controls
Controlled release polymeric systems can be classified on the basis of the mechanism
controlling the release of the incorporated drug.
DIFFUSION CONTROLLED SYSTEMS
a) Reservoir systems
In these systems, core of the drug is surrounded by a swollen or non swollen polymer
film and diffusion of the drug through the polymer is the rate limiting step. Reservoir
devices are also of two types. Reservoir without a rate controlling system. Reservoirs
that lack rate control include hollow fibers, gels and dialysis tubing. Reservoirs with
rate controlling systems include erodible polymeric matrices, polymer membranes,
monolithic matrices and coated particles25.
b) Matrix systems
In these systems, the drug in uniformly distributed throughout a solid polymer. The
drug diffusion through the polymer matrix is the rate limiting step.
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CHEMICALLY CONTROLLED SYSTEMS
a) Bioerodable System:
In these systems, a drug is uniformly distributed throughout the polymer, and the
drug  is released by diffusion as the polymer phase decreases with time. As the
polymer surrounding the drug resorbed, the drug escapes.
b) Pendant Chain System:
In these systems, the drug is chemically bound to a polymer back bone and drug
release occurs via hydrolytic or enzymatic cleavage.
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2.NEED FOR THE STUDY
In conventional mode of administration many drugs do not reach target areas
in the body  in sufficient concentration because of premature inactivation and
excretion. This problem can be overcome by administering the drug directly to the
intended site of action with lesser dose. In recent years, novel drug delivery systems
are becoming popular as pharmaceutical technologists today are able to provide the
drug delivery systems with very precise control over drug release for a prolonged
period of time eliminating the need for frequent dosing and minimizing side effects,
thereby increasing patient compliance and comfort.
The most common dental infections include dental carries, dental alveolar infections,
gingivitis, periodontitis, deep facial face infections and osteomyelities. If untreated,
dental  infections  spread and contribute to  polymicrobial  infections at  other sites.
Among the above mentioned dental infections periodontitis, a common cause of tooth
lose is one of the chronic infections of oral cavity, primarily caused by gram positive,
gram negative and anaerobic bacteria that reside in sublingual area.
The systemic administration of drugs for treating dental conditions can reach the
systemic circulation via serum and hence the microorganisms at the depth of the
periodontal sites and also the possible organisms residing within gingiva and capable
of eliminating pathogens not only from periodontal lesion but from oral cavity as
well.
The greatest disadvantage of systemic administration of antimicrobials for
periodontitis is that, the drug is diluted several thousand folds before it reaches the
site and exposes the rest of the body to potential side effects. In some patients, loss of
19
attachments develops very rapidly and continuously in spite of proper therapy.
A site specific system aims at delivering the therapeutic agent at sufficient levels
inside the pocket and at the same time minimizing the side effects associated with
systemic drug
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3.AIMS&OBJECTIVES
The purpose of the present investigation is to develop the polymeric inserts (chitosan)
containing different concentration of the anti-bacterial agent Doxycycline for local
controlled drug delivery into periodontal pockets. Apart from this, an investigational
study is planned to prolong the drug release for more number of days by formulating
in to multilayer (polymer) inserts.
Specific objectives of the present investigation are as follows,
1. To develop a chitosan single layer with different concentration of doxycycline
hyclate (10%, 20% and 30%).
2. To develop a chitosan multilayer inserts containing doxycycline hyclate.
3. Evaluation of prepared inserts for physical characteristics such as
 Thickness and Weight Variation
 Folding Endurance
 Percentage  Moisture Loss
 Percentage Moisture Absorption
 Drug Content Uniformity
 Tensile Strength
 Differential Scanning Calorimetry
 Fourier Transfer – Infrared Spectroscopy(FT-IR)
 Water Uptake and Swelling Index
4. To study static dissolution pattern of the drug dosage forms.
5. In-vitro antibacterial activity.
6. Stability studies at different temperature as per ICH guidelines.
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4. DRUG PROFILE
DOXYCYLINE HYCLATE:
Chemical Name:-(4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)1,4,4a,5,5a,6,
11,12aoctahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene
carboxamide monohydrochloride, compound with ethyl alcohol (2:1), mono-hydrate;
[4S-(4α,4aα,5α,5aα,6α, 12aα)]-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-
3,5,10, 12, 12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene carboxamide
monohydrochloride26.
 Structure:-
 Molecular formula :- (C22H24N2O8 · HCl)2 · C2H6O ·H2O
 Molecular weight :- 444.435 g/mol
 Melting point :- 201-202 0C
 Physical form :- yellow crystalline powder
 Solubility :- Freely soluble in water acetic acid, 6.6 pH buffer and
acetic acid
 Pharmacology:
Tetracyclines are readily absorbed and are bound to plasma proteins in varying
degree. They are concentrated by the liver in the bile, and excreted in the urine and
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feces at high concentrations and in a biologically active form. Doxycycline is virtually
completely absorbed after oral administration.Following a 200 mg dose, normal
adult volunteers averaged peak serum levels of 2.6mcg/ml of doxycycline at 2 hours
decreasing to 1. 45 mcg/ml at 24 hours.
Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with
normal function (creatinine clearance about 75 ml/min). This percentage excretion
may fall as low as 15%/72 hours in individuals with severe renal insufficiency
(creatinine clearance below 10mL/min). Studies have shown no significant difference
in serum half-life of Doxycycline (range 18-22 hours) in individuals with normal and
severely impaired renal function.
Hemodialysis does not alter serum half-life. Results of animal studies indicate that
tetracycline cross the placenta and are found in fetal tissues27.
 Mechanism of action:
Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of
bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the
50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and
inhibiting bacterial protein synthesis. Doxycycline prevents the normal function of the
apicoplast of Plasmodium falciparum, a malaria causing organism27.
 Pharmacokinetics:
1 Absorption Complete, no interference by food
2 Protein binding High
3 Bioavailability 90-95 %
4 Plasma half life 18-22 hrs
5 Metabolism Hepatic
6 Excretion Urine, feces
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 Elimination: Half-life :- 18-22 hours
 Drug interactions:
If used in conjunction with the anesthetic methoxyflurane there can be severe or fatal
kidney damage. May interact with anticoagulants and its effectiveness is lowered by
over the counter antacids and bismuth subsalicylate, barbiturates, the anticonvulsants
carbamazepine and phenytoin. Tetracycline blocks the action of bactericidal
antibiotics such as penicillin and should not be given in combination with such
antibiotics.
 Contraindications:
Doxycycline and other tetracyclines must not be given to women during the last half
of pregnancy or to children under the age of eight. It can affect development of the
skeleton in the fetus and can cause discoloration and malformation of the teeth. Any
demonstrated sensitivity to tetracycline contraindicates use. Some people may show
increased sensitivity to sunlight28.
 Side effects:
Losses of appetite, nausea, vomiting and diarrhea have been observed.
Hypersensitivity, anaphylaxis, and exacerbation of immune disorders have been seen.
Hemolytic anemia and other disturbances of the white cell population of the blood are
known28.
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5.POLYMER PROFILE
CHITOSAN
 Synonyms :- 2-Amino-2-deoxy-(1,4)-β-D-glucopyranan; deacetylated chitin;
deacetylchitin; β-1,4-poly-Dglucosamine; poly-D-glucosamine; poly-(1,4-β-D-
glucopyranosamine).
 Chemical Name and CAS Registry Number :- Poly-β-(1,4)-2-Amino-2-deoxy-
D-glucose [9012-76-4]
 Molecular weight :- 10000-1000000
 Origin of Chitosan
One reason why chitosan has become of interest is undoubtedly because it can be
obtained from natural sources that are abundant and renewable. Chitosan is prepared
from chitin, the polymer second most abundant in nature after cellulose (Roberts,
1992). Chitin is the primary  structural component of the outer skeletons of
crustaceans, and of many other species such as molluscs, insects and fungi. The role
played by chitin is similar to the roles played by cellulose in plants and collagen in
higher animals. It is a reinforcing material, which occurs in three polymorphic forms,
and chitin. Where hardness in needed chitin is found, where flexibility is required and
chitin occurs. Chitin is inert in aqueous environment. This property limits the use of
chitin as such. Chitosan is prepared from chitin to obtain a more reactive polymer29.
Physical Properties
• Particle size < 30nm
• Density 1.35 – 1.49 g/cc
• Solubility: Insoluble in water but soluble in acids.
 pH (1% w/v solution) : 4.0–6.0
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 Solubility:
Sparingly soluble in water; practically insoluble in ethanol (95%), other organic
solvents, neutral or alkali solutions at pH above approximately 6.5.
 Description:
Chitosan occurs as odorless, white or creamy-white powder or flakes. Fiber formation
is quite common during precipitation and the chitosan may look 'cottonlike'.
 Functional Category:
Coating agent, disintegrate, film-forming agent, mucoadhesive, tablet binder,
viscosity increasing agent.
 Structure:
Chitosan is a linear polysaccharide consisting of ß (1-4)-linked 2-amino- 2-deoxy-D-
glucose (D-glucosamine) and 2-acetamido-2-deoxy-D-glucose (N-acetylglucosamine)
units. The structure of chitosan is very similar to that of cellulose (made up of ß (1-4)-
linked D-glucose units), in which there are hydroxyl groups at C2 positions of the
glucose rings30.
 Mechanism of action:
Chitosan formulations can easily be prepared using conventional tableting or
granulating methods. The simplest way of achieving slow release of drugs by means
of chitosan is to employ it as a gel-forming excipient in matrix-type formulations.
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Retardant effects of chitosan on drug release were noticed as early as the 1980s.
Chitosan was found to decrease rates of release  of drugs from tablets during
dissolution tests at acidic and slightly acidic pH levels (Kawashima et al., 1985;
Acartürk, 1989). However, Akbua (1993a), who carried out studies at higher pH
levels (pH 7.4), reported that chitosan exhibited no slow-release properties29, 30.
 Features:
The Chitosan (CS) is known to be non-toxic and odorless. Chitosan has received
considerable attention as a possible pharmaceutical excipient in recent decades
Chitosan is an excellent polymer to be used for buccal delivery because it has
muco/bioadhesive properties and can act as an absorption enhancer. Chitosan gives
prolonged release of the drug in the buccal cavity improving the antimicrobial activity
of the drug. Chitosan periodontal film with drug incorporated have antimicrobial
activity due to the chitosan. The buccal bilayered devices (bilaminated films,) using a
mixture of drugs and chitosan, with or without anionic crosslinking polymers has
promising potential for use in controlled delivery in the oral cavity30.
 Properties of Chitosan:
Cationic Polyamine
Chitosan has highly charged density at pH < 6.5 i.e. one charge per glycosamine unit.
The ionic character along with reactive functional group in chitosan has made it a
suitable polymer for utilization  in controlled release technology. The molecular
weight of chitosan varies from 50 KDa to 2000 KDa29.
Amenable to Chemical Modifications
Chitosan is linear polyamine where amino groups are readily available for chemical
reaction and salt formation with acids. The possibility of amino groups suggests that
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chitosan could be used to formulate therapeutic system where the drug release kinetics
depends on erosion pathway of polymeric network due to hydrolysis of cross-linking
bonds.
Flocculation and Mucoadhesive Properties
Chitosan formulations exhibit ease of delivery [30, 31] a good retention at the
application site, and a controlled release of the drug. Chitosan is shown to have an
antimicrobial activity against P. gingivalis and higher activity with high molecular
weight chitosan.The combination of chitosan with chlorhexidin showed a significant
higher activity, when compared to that of chlorhexidine alone, which would provide
chlorhexidine application at lower concentrations thus avoiding its unwanted side
effects. Chitosan films and gels seem to be promising delivery systems for local
therapy of periodontal diseases with its bioadhesive property and antimicrobial
activity 32.
Biological Properties
Its biological properties include non toxicity, biodegradability and biocompatibility.
N-acyl chitosan showed the best blood biocompatibility due to increase of surface
hydrophilicity and induction in hydrophilic and hydrophobic properties at the surface.
CLINICAL APPLICATION
Wound Healing
Chitin and chitosan are effective wound healing accelerators, in both animal and
human tests, the surgical adjuncts of regenerated chitin are physiologically
compatible, bioabsorbable and effective wound healing accelerators. N-Carboxybutyl
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chitosan was studied in wound healing in rabbits; where complete re-epithelialization
was observed with all the epithelial layers represented on 30th day of treatment, an
interesting role in tissue reconstruction. Chitosan has also been used to prepare
bandages for wound healing.
The physiological compatibility of chitin with living tissues, combined with its ability
to form readily sulfate esters which are non thrombogenic appears to make chitin a
most promising candidate for prosthetic structural devices of any desired shape or
sizes31, 33.
Haemostatic Agent
Chitosan solution formed a coagulum in contact with whole blood, where the possible
mechanism appeared to be a reaction between red cell membrane and the chitosan
solution leading to cross linkage or re-polymerisation. Chitosan is an effective and
adequate homeostatic agent even under the most severe conditions of anticoagulation.
Introduction of uronic acid carboxyl groups increases the anticoagulant activity of
sulfacted chitosan.
Application in Dentistry
Many advantages are attainable by use of chitosan in periodontology such as decrease
subjective symptomatology, good homeostatic action, and delayed release of
antibiotics, wound healing acceleration and better condition for asepsis. Chitosan has
been used in 24 patients all of which recovered completely. No allergic reactions or
infections took place. Chitosan could be used as transparent membrane or preferably
as a thin powder soaked in antibiotic solution, it accelerated wound healing, promoted
regular fibrin formation and favored the epithelialization.
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6. REVIEW OF LITERATURE
REVIEW OF PAST STUDY DONE ON DOXCYCLINE DRUG
 Gaurav Tiwari1 et al., release studies of metronidazole and doxycycline from
polycaprolactone films prepared by solvent evaporation. metronidazole and
doxycycline with different antibacterial spectra are proposed to be formulated as
combination therapy to have a broader antibacterial therapy, which is effective
against both aerobic and anaerobic periodontal microflora. Simultaneous use of
metronidazole and doxycycline is effective against wide range of periodontal
pathogens. Metronidazole and doxycycline release from polycaprolactone films
was zero-order after an initial period. Significant burst effects were observed with
metronidazole and doxycycline (5, 10% w/w) 34.
 Mohammed M Al-Abdaly, et al., studied the effects of topical application of
Atridox (Doxycycline gel) in management of chronic periodontitis. This study
was carried out on 15 patients (aged 25-55) with chronic periodontitis. They were
received scaling and root planning (SRP) alone in one side and SRP plus Atridox
(Doxycycline gel) in other side. Each individual was subjected to the following
measurements. Evaluation of the clinical parameters pre and post treatment to
detect the outcome of the treatment modality and Denial plaque samples initially
and at 3,  6, 9 and 12 months were obtained for microbiological evaluation.
Atridox (Doxycycline gel) delivered locally into periodontal disease sites reduced
all subgingival bacteria. Both treatment and modality led to a highly statistically
significant reduction in microbiological counts as well as clinical parameters
applied. No clinical relevant side effects were observed35.
 Thawatchai Phaechamud et al., studied the chitosan sponges loaded with
Doxycycline hyclate and their antibacterial activities. The pore density of
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chitosan  sponge prepared  with freeze drying  technique was  increased as  the
higher concentration of chitosan solution was used. The sponge prepared from
10% w/w of the chitosan solution and crosslinking with glutaraldehyde solution
was utilized for loading with doxycycline hyclate. The drug release and
sustainable antibacterial activity of fabricated sponge were assessed using
dissolution test and agar diffusion test, respectively. Drug release from  non-
crosslinked sponge into phosphate buffer pH7.4 was slower than that from
crosslinked sponge since the former could absorb the medium and form gel to
retard the initial drug diffusion. Sustainable antibacterial activity of developed
sponge was evident against S. aureus and E. coli. Results indicated that the in
vitro release profile and antibacterial efficiency of doxycycline hyclate could be
sustained using chitosan sponge36.
 N. Damodharan et al., developed delayed release doxycycline tablets for
targeting to small intestine tablets were prepared by wet granulation method and
enteric coating of tablets (conventional standard coating technique). Using pH
depended polymers like Eudragit and HPMC Phthalate. Preformulation studies
like angle  of repose, bulk density, tapped density, porosity, Carr's index,
Hausner's ratio were performed. Six batches (F1 to F6) were formulated and
evaluated for hardness, friability, weight variation, drug content, disintegration
and in‐vitro dissolution. Among the six batches, batch F4 was showed 94% drug
release and was considered as best formulation37.
 S.Shanmuganathan N et al., prepared Doxycycline loaded
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chitosan microspheres were developed using a novel water-in-oil emulsion
technique, involving oil phase ionic gelation. Microspheres were prepared by
using 6% v/v of chitosan (3% w/v in acetic acid), soya oil–n-octanol oil mixture
(1:2 v/v) as continuous phase and 5% span 80 as emulsifier. Doxycycline was
entrapped by equilibrium swelling method with 8.4% total entrapment. The drug-
loaded spheres were spherical with smooth surface morphology. The MTT assay
showed that doxycycline-loaded microspheres were able to improve the
percentage cell viability in comparison to the pure drug. In vitro release studies
showed that a burst release of 42% in 6 h was achieved and maintained an
equilibrium concentration of 72% in 24 h. Assessment of antibacterial activity
showed that doxycycline was able to exhibit a minimum microbicidal
concentration (MIC) of 16.5, 17.4, 11.2 and 98.3μg against Klebsiella
pneumoniae (ATCC15380), Escherichiacoli (ATCC25922), Staphylo
coccusaureus (ATCC9144) and Pseudomonas aeruginosa (ATCC 25619),
respectively. Gelatin zymography studies revealed that it could inhibit MMP 2
and MMP9 at sub-antimicrobial concentration. The present investigation provides
scope for using doxycycline-loaded chitosan microspheres for healing
infected wounds39.
 MarcoAntonio Botelho etal., aim of this study was to test the efficacy of a
locally applied 8.5% nanostructure doxycycline (DOX) gel in preventing alveolar
bone loss in experimental periodontal disease (EPD) in rats by using the tapping
mode atomic force microscopy (AFM). Material and method EPD was induced in
24 Wister rats. Animals were treated with the doxycycline gel topically,
immediately after EPD induction, and 3 times a day during 11 days. Four groups
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(n=6) were formed as follows: each group (animals not subjected to EPD nor
treated); non-treated (NT) group (animals subjected to EPD, but not treated);
vehicle gel (VG) group (animals subjected to EPD and treated with topical gel
vehicle); and DOX group (test group) animals subjected to EPD and treated with
the 8.5% DOX gel. In order to investigate topographical changes in histological
sections, a novel simple method was used for sample preparation, by etching
sections from paraffin-embedded specimens with xylol. Results: comparing the
AFM images, several grooves were observed on the surface of the alveolar bone
and other periodontal structures in the NT and VG groups, with significantly
greater depths when compared to the DOX group40.
 Narayana Charyulu et al., developed strips of chitosan polymer 2% containing
ciprofloxacin Hcl, norfloxacin and doxycycline by solution casting method using
1% acetic acid as casting solvent. Macroscopical features revealed that drugs
were dissolved in the polymer. The DSC and UV scan studies confirmed the
absence of any chemical interaction between the drugs and polymer. Short term
stability studies were carried out at different temperature. The static dissolution
showed a burst release effect initially followed by  a progressive fall in the
release. Mass balance studies did not deviate by more than 3%. It was observed
from the above studies that the chitosan strips have an ability to sustain the
release of drugs and more useful as slow release device for periodontal disease41.
 Heba A. Gad et al., formulated in situ implants containing doxycycline
hydrochloride and/or secnidazole that could be used in the treatment of
periodontitis by direct periodontal intrapocket administration. Biodegradable
polymers [poly (lactide) (PLA) and poly (lactide-co-glycolide) (PLGA)], each
polymer in two concentrations 25%w/w, 35%w/w were used to formulate the
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insitu implants. The rheological behavior, in vitro drug release and the
antimicrobial activity of the prepared implants were evaluated. Increasing the
concentration of each polymer increases the viscosity and decreases the percent
of the drugs released after 24 h. PLA implants showed a slower drugs release rate
an PLGA implants in which the implants composed of 25% PLGA showed the
fastest drugs release. The in vitro drug release and antimicrobial activity results
were compared with results   of Atridox®. Results revealed   that   the
pharmaceutical formulation based on 25% PLGA containing secnidazole and
doxycycline hydrochloride has promising activity in treating periodontitis in
comparison with Atridox42.
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PAST WORK DONE ON POLYMER (CHITOSAN)
 Shankraiah et al. were prepared Flexible films of sparfloxacin for periodontitis
treatment for easy insertion into periodontal pockets. The optimum concentration
of chitosan used for the preparation of strips was found to be 2% w/v, because at
this concentration the strips were flexible and easily removable from the die. An
optimum concentration of drug to be loaded was found to be 30% w/v to the
polymer or less than that. For the present investigation, chitosan strips containing
sparfloxacin with three different concentrations, i.e.10, 20, and 30% to the weight
of the polymer, were prepared using the solvent casting method. All the
formulations were found to contain almost uniform quantity  of drug as per
content uniformity studies, indicating reproducibility of the technique43.
 Dan Mei et al., The objective of this work was to assess and compare the
absorption promoting effect of different molecular-weight chitosans, trimethyl
chitosans and thiolated chitosans for intranasal absorption of 2,3,5,6-
tetramethylpyrazine phosphate (TMPP). An in situ nasal perfusion technique in
rats was utilized to test the rate and extent of TMPP absorption in situ. In vivo
studies were carried out in rats and the pharmacokinetic parameters were
calculated and compared  with  that  of intravenous  injection.  All  the chitosan
derivatives investigated could enhance the intranasal absorption of TMPP
significantly. However, thiolation could not improve the absorption-enhancing
capacity of chitosan remarkably even when the thiolation ratio was as high as
152 lmol/g. In contrast, trimethylated chitosan exhibited stronger absorption-
enhancing ability than the homopolymer chitosan. The permeation enhancing
effect of chitosan increased with increasing molecular weight up to Mw 100 kDa.
In vivo studies indicated that chitosan 100 kDa and TMC 50 kDa had comparable
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absorption-enhancing effect but chitosan 100 kDa functioned for more than 120
min versus 90 min for TMC. A good correlation was found between the in situ
absorption data and plasma concentration in vivo for the polymers investigated.
This study demonstrated that both chitosan structural features and chitosan
molecular weight play  a key role on promoting  the intranasal absorption of
TMPP. Taking safety reason into account, chitosan 100 kDa is the most
promising as an intranasal absorption enhancer.44.
 Barat R et al., chitosan based  metronidazole inserts  were fabricated by the
casting method and characterized with respect to mass and thickness uniformity,
metronidazole loading and in vitro metronidazole release kinetics. The fabricated
inserts exhibited satisfactory physical characteristics. The mass of inserts was in
the range of 5.63 ± 0.42 to 6.04±0.89 mg. The thickness ranged from 0.46 ±0.06
to 0.49 ±0.08 mm. Metronidazole loading was in the range of 0.98 ±0.09 to
1.07±0.07 mg except for batch CM3 with MZ loading of 2.01V± 0.08. The
inserts exhibited an initial burst release at the end of 24 hr, irrespective of drug to
polymer ratio plasticizer content or cross linked. However further drug release
was sustained over the next 6 days, cross linking to 10% (m/m) of glutaraldehyde
inhibited the burst release by~30 % and increased the mean dissolution time
(MDT) from 0.67 to 8.59 days. The decrease in drug release was a result of
reduced permeability of chitosan due to cross linking45.
 Senel S, IkicI G.et.al., developed the formulation containing chitosan for local
delivery of chlorhexidine gluconate (chx) to the oral cavity. Gels at (1 or 2%
concentration) or film forms of chitosan were prepared containing 0.1-0.2% chx
(chlorhexidine gluconate) and there in vitro release properties were studied. The
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antifungal activity of chitosan itself as well as their various formulations
containing chlorhexidine gluconate (chx) was also examined. Release of
chlorhexidine gluconate (chx) from gels was maintained for 3hr. A prolong
release was observed with film formulation. No lag time was observed in release
of chx from either gels or films. The highest antifungal activity was obtained with
2% chitosan gel containing 0.1% chlorhexidine gluconate (chx.)46.
 Amal Hassan El-Kamel et al., developed a local, oral mucoadhesive
metronidazole benzoate (MET) delivery system that can be applied and removed
by the patient for the treatment of periodontal diseases. Mucoadhesive
micromatricial chitosan poly(ε-caprolactone) (CH/PCL) films and chitosan films
were prepared. Thermal behavior, morphology, and particle size measurements
were used to evaluate the prepared films. The effect of different molar masses of
CH and different ratios of medium M.wt.molar mass chitosan (MCH): PCL on
water absorption, in vitro bioadhesion, mechanical properties, and in vitro drug
release was examined47.
 Ritu B. Dixit et al., developed cefadroxil drug loaded biopolymeric films of
chitosan-furfural schiff base were prepared by reacting chitosan with furfural in
presence of acetic acid and perchloric acid respectively for the external use.
Prepared films were evaluated for their strength, swelling index, thickness, drug
content, uniformity, tensile strength, percent elongation, FTIR spectral analysis
and SEM. The results of in vitro diffusion studies revealed that the films
exhibited enhanced drug diffusion as compared to the films prepared using
untreated chitosan. The films also demonstrated well to moderate antibacterial
activities against selective gram positive and gram negative bacteria48.
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 Mohammed Gulzar Ahmed et al, developed chitosan strips containing
Gatifloxacin (10%, 20% and 30% to the weight of polymer) were prepared by
solution casting method using 1% v/v acetic acid in water. Further strips
containing 30% gatifloxacin were cross-linked by exposing to the vapours of 2%
v/v glutaraldehyde in water intended to extend the release. The prepared films
were evaluated for their thickness, content uniformity, weight variation, tensile
strength, hardness and in-vitro dissolution. The average weight and thickness of
both the cross linked and uncross-linked strips were uniform. There was a
reduction in the tensile strength and increase in hardness when the films were
cross-linked. Static dissolution studies showed a burst release initially followed
by a progressive fall in the release of the drug and extended up to 19 days once
the strips were cross-linked. Release kinetics of gatifloxacin from chitosan strips
followed the higuchi’s diffusional model and also showed zero order release
profile49.
 S.Sangeetha et al., Nanoparticle made up of biodegradable carrier such as
chitosan have advantage of providing stearic interference in the systemic
circulation. Cytarabine nanospheres were prepared by ionic gelation method with
an objective of improving its intracellular targeting and thereby targeting the
cancer cells. The average particle size determined through SEM was found to be
466.45 ± 5.32 nm. The average drug loading was found to be 62% for the batch
loaded with 1.50 mg/ml of drug when compared to other batches. The cumulative
percentage of drug release from all the drug loaded batches at 18 hours was found
to be in the range of 86.73 % to 93.50%.Among the four batches of nanoparticles
formulated the batch containing  1.50mg  of drug/ml of polymer showed the
highest of about 93.50% of release. Release of drug from the matrix was by non-
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Fickian analomous diffusion mechanism. Invivo bio distribution studies showed
that the Cytarabine in the form of nanoparticles was having a greater bio
distribution when compared to free drug in different organs like liver, spleen,
lungs and kidney50.
 K. Bansal et al., develop  satranidazole-containing mucoadhesive gel for the
treatment  of periodontitis.  Different  mucoadhesive gels  were prepared, using
various gelling agents like sodium carboxymethylcellulose (SCMC), poloxamer
407, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methyl
cellulose, and the mucoadhesive polymer carbopol 934P. The selected
formulations were studied for different mechanical properties, such as
mucoadhesive  strength, hardness, compressibility, adhesiveness, and
cohesiveness through texture profile analyzer. In vitro satranidazole release from
the prepared formulations was also determined and compared  with marketed
preparation  of metronidazole.  The formulation SC30 (Containing SCMC 3%
w/v)   showed maximum mucoadhesive strength (167.72 ± 3.76 g) and
adhesiveness (−46.23 ± 0.34 Nmm), with low hardness (9.81 ± 0.04 N) and
compressibility (40.05 ± 0.48 Nmm) and moderate cohesiveness (0.87 ± 0.01).
SC30 formulation exhibited long-term release. Thus, SC30 gel was evaluated for
its clinical effectiveness along with marketed metronidazole gel. At the end of the
study (42 days of clinical studies), both formulations were found to significantly
reduce the probing depth, plaque index, gingival index, calculus criteria, and
bleeding index. However, the SC30 gel was more effective in reducing the above
parameters than marketed metronidazole gel. This study confirmed the
acceptability and effectiveness of satranidazole gel for treatment of
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periodontitis.51.
 Mohammed Gulzar Ahmed et al., prepared Chitosan films containing
tetracycline in three different concentrations were prepared by  the solution
casting method, using 1% v/v acetic acid solution for therapy of periodontal
disease. The prepared films were evaluated for various properties. The stability
studies did not show any significant changes. Static dissolution studies showed a
burst release initially followed by a progressive fall in the release of the drug, and
also showed extended release when cross-linking was attempted. The in-vitro
release kinetics of tetracycline followed the zero order patterns52.
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REVIEW STUDY DONE ON LOCAL DRUG DELIVERY SYSTEM
 Shankraiah et al., developed a sustained release device containing ornidazole for
insertion within periodontal pockets. Cast films of ethyl cellulose with dibutyl
phthalate as plasticizer, containing ornidazole were prepared. The films  were
evaluated for thickness, folding endurance, weight variation, content uniformity,
tensile strength, in vitro antibacterial activity and in vitro release study.   The
release data obtained were subjected for release kinetics study. The study revealed
that drug release was found to be diffusion controlled with sustained release of
ornidazole over a period of nine days within the periodontal pocket53.
 G.L.Prabhushankar et al., developed a levofloxacin dental films for periodontitis
between levofloxacin and  polymers.The films were evaluated for their thickness
uniformity, folding endurance, weight uniformity, content uniformity, tensile
strength, surface pH and in vitro antibacterial activity54.
 Mastiholimath V.S et al., site specific one time delivery of ornidazole an
antimicrobial compound with excellent activity against anaerobic micro-organism
in the treatement of periodontal disease was prepared by solvent casting technique
using ethyl cellulose, hydroxyl propyl cellulose, hydroxypropylmethyl cellulose
K4M and eudragit RL-100 With dibutyl phthalate is plasticizer.The
physiochemical parameters like thickness, weight variation, content uniformity
and release characteristics were evaluated. The drug release was initially high on
day one to achieve immediate therapeutic level of drug in pocket, followed by
marked fall in release by day two and progressive moderate release profile to
maintain therapeutic level following anomalous transport release profile
mechanism. Formulation V6 released 97.07 % of drug at the end of 120 hour
and was considered as best formulation. In vitro antibacterial activity was carried
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out on Streptococcus Mutans55.
 Hong Hua., Chi ping.et al., prepared multilayer membranes which were loaded
with drug for guided tissue regeneration were prepared using an immersed
precipitation phase   inversion technique, single   layer, bilyer and trilayer
mechanism were fabricated with chitosan used as carrier and tinidazole as
medicine model which was loaded on the membrane. The influence of layer on
structure and properties of membrane were studied by SEM, UV spectrometer
and mechanical test. Drug release properties of three types of layer membrane
also investigated. The result showed that release rate could be shown in both
bilayer and trilayer membrane (11 days and 14 days respectively) and trilayer
membrane lastest the longest. After a process of rapid release, the concentration
of tinidazole which was released by the membrane was maintained at an efficient
dosage level compared with single  layer and bilayer membranes, be found
trilayer membrane could play  a role in controlling  low rate drug release
especially at the early stage of release, and keep an efficient dosage at affected
part for a long period of time. The loss of drug which loaded on membrane
decreased from 84.6% for Single layer to 13.04% for trilayer the mechanical
strength of three types of membrane were detected an showed that it could meet
the requirements of clinical practice the membranes specially with trilayer could
be more valuable in application56.
 Sujatha Muchalambet al., Specific one time continuous delivery of sparfloxacin
an antimicrobial compound with excellent activity against anaerobic micro-
organisms in the treatment of periodontal disease was prepared by using solvent
casting technique using hydroxy propyl cellulose, hydroxy methyl cellulose,
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eudragit RL-100 and ethyl cellulose with dibutyl phthalate as plasticizer. The
physicochemical parameters like thickness, weight variation, content uniformity
and release characteristics were evaluated. The drug release was initially high on
day one to achieve immediate therapeutic level of drug in periodontal pocket
followed by marked fall in release by day two with progressive moderate release
profile to maintain therapeutic level following anamolous transport mechanism.
Formulation F4 released 90.24% of drug at the end of 120 hr and was considered
as best formulation. In vitro antibacterial activity was carried out on
Streptococcus mutans57.
 K. Schwach-Abdellaoui et al., Periodontitis is an inflammatory disease of the
supporting tissues of the teeth caused by groups of specific microorganisms.
Aggressive forms of periodontitis can be localized or generalized. The concept
that localized problem sites may be treated by local drug delivery appears
attractive as the antimicrobial agent is delivered within periodontal pockets and
the therapy is targeted on specific pathogenic microorganisms. Local delivery of
antimicrobial agents using controlled release systems should be considered as
adjunctive to mechanical debridement for the treatment of localized forms of
periodontal destruction. This article reviews various types of delivery systems
evaluated in practical periodontal therapy. Despite the large number of studies
showing an enhanced effectiveness of local antibiotherapy, there are insufficient
Comparative data to support any of the local delivery system58.
 Vineet Bhardwaj et al., Chitosan films of different concentrations containing
ofloxacin were prepared by solvent casting method. Some of the drug-loaded
films were crosslinked with 2% gluteraldehyde for 1,2 and3 hrs, respectively.
The films were then evaluated for their physicochemical properties including
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weight variation, thickness, moisture loss, tensile strength, elongation, in vitro
anti bacterial activity and in vitro release. In vitro drug release data indicate that
the films showed an initial burst release followed by sustained release of the
drug. The drug-loaded films that were not crosslinked had effect on for up to 9
days and the films which are crosslinked for different duration shows release
depended on concentration of chitosan in different films (1%, 2%, 3%)59.
 Steinberg et al., developed a degradable sustained release device composed of a
cross linked protein containing chlorhexidine. The in-vitro release profile of
chlorhexidine (from the degradable films) was altered by the amount of
chlorhexidine loaded, cross- linking density of the polymer and type of
chlorhexidine salt. This work demonstrated the release of chlorhexidine and
showed that the degradation of the matrix can be controlled by factors in the
formulation60.
 Hitzig et al., observed 28 patients suffering from adult periodontitis for a span of
3 months. They treated the patients with 5% metronidazole in collagen device in
periodontal pocket more than 5 mm, keeping mechanical root debridement as
control. Analysis of data from 28 patients indicated that both debridement and
metronidazole therapy decrease pocket depth, bleeding on probing and gingival
index, but results were significantly better with metronidazole61.
 Kurien et al., evaluated the efficacy of ciprofloxacin and norfloxacin when used
in a sustained release system in periodontal pockets. Sustained release inserts
were prepared using ethyl cellulose (EC) and hydroxypropyl methyl cellulose as
(HPMC) co-polymers along with polyvinyl pyrrolidine (PVP), drug and ßeta
cyclodextrin complex. The rate of release of the drug was controlled and
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prolonged for 14 days period. It was found that both norfloxacin and
ciprofloxacin appeared to be equally effective in reducing periodontal pathogens
and in controlling the inflammation compared with the placebo treated control
sites62.
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7. MATERIAL AND METHODS
MATERIALS
Drug, Polymer and Chemicals:
S.No Name of the Chemicals Supplier Name
1. Doxycycline hyclate Micro labs, Banglore.
2. Chitosan Central Institute of Fisheries Technology ,
Metysapuri,Cochin.
3. Acetic acid S-difine Chemicals., Mumbai
4. Potassium hydrogen ortho
Phosphate
S-difine Chemicals., Mumbai
5. Sodium hydroxide S-difine Chemicals., Mumbai
6. Glutaraldehyde S-difine Chemicals., Mumbai
7. Calcium chloride S-difine Chemicals., Mumbai
8. Anhydrous aluminum chloride S-difine Chemicals., Mumbai
9. Acetone S-difine Chemicals., Mumbai
All the other chemicals used in this study are of analytical reagent grade (A.R. grade).
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List of Instruments Used For Formulation and Evaluation
S.No Instruments Supplier
1. UV/Visible Spectrophotometer 1700 Shimadzu
2. Vortex mixer VM 301 Remi., Mumbai
3. Digital pH meter HANNA Instruments, Italy
4. Electronic weighing Balance Essaie-Teraoka Ltd., USA
5. Tensile strength tester Digital testing apparatus
6. Digital screw gauge Mitutoyo., Japan
7. FT-IR Shimadzu
8. Levelled glass moulds Designed in our laboratory
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4. EXPERIMENTAL METHODS:
1. PREFORMULATION STUDIES
Preformulation testing is the first step in the rational development of dosage form of
the drug. It can be defined as an investigation of physical and chemical properties of
drug substances, alone and when combined with excipents. The overall objective of
preformulation testing is to generate information useful to the formulator in
developing stable and bioavailable dosage forms, which can be mass produced.
A thorough understanding of physicochemical properties may ultimately
provide a rational for formulation design or support the need for molecular
modification or nearly conform that there are more significant barriers to the
compounds development. The goals of the program therefore are to establishment
the necessary physicochemical characteristics of new drug substances
 Determine its kinetic release rate profile.
 To establish its compatibility with different excipents.
Hence, preformulation studies on obtained drug sample include physical tests and
compatibility studies.
 Melting Point determination:
Melting point was determined by taking small amount of drug in a capillary tube
whose one end was sealed by melting. The capillary tube was placed in the Digital
melting point apparatus.   The temperature was slowly increased with simultaneous
observation of the sample.   The temperature at which the drug starts melting was
recorded as melting point. This process was performed three times for Doxycycline.
The mean of three readings was recorded.
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2. COMPATIBILITY STUDIES
Drug- Excipient interaction studies:
The successful formulation of a stable and effective solid dosage form depends on the
careful selection of the excipients that are added to facilitate administration, promote
the consistent release and bioavailability of the drug.
FTIR and DSC studies can be used to investigate and predict any physicochemical
interactions between components in a formulation and can therefore be applied to the
selection of suitable chemically compatible excipients.
a. Fourier transforms infrared (FTIR) Spectral studies:
FTIR spectra were taken on a Shimadzu instrument to investigate the  possible
chemical interactions between the drug and the blend matrix. FTIR spectra of plain
doxycycline and physical mixture were scanned in the range between 4000 and 500
cm-1. The spectra’s are compared with the peak intensities found in a standard
reference.
Sample preparation
Samples are taken in the ratio of 1:100, where 1 is the amount of sample taken and
100 was the amount of potassium bromide taken and triturated with due precaution
not to contact with the moisture, which may interfere with the test. Samples were
crushed with KBr to get the pellets by applying a pressure of 300 kg/cm2. The sample
along with blank (KBr), reference standard drug are placed in order on the disk
provided. Peaks obtained in FTIR are compared to that of standard peaks for any
significant change64.
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b. Differential scanning calorimetry (DSC):
The DSC measurements were performing on a DSC – 61000 (Seiko Instruments,
Japan) differential scanning colorimeter with thermal analyzer. All accurately
weighed samples (about 5 mg of doxycycline and chitosan) were placed in a sealed
aluminum pans, before heating under nitrogen flow (20 ml/min) at a scanning rate of
200C per min from 100 to 3000C.  An empty aluminum pan was used as reference65.
3. ANALYTICAL METHODS
a. PREPARATION OF REAGENTS
Preparation of 1% v/v acetic acid:
Accurately measured 1 ml of concentrated acetic acid was dissolved in 100 ml of
distilled water.
Potassium dihydrogen orthophosphate 0.2M:
Dissolved 27.218 grams of potassium dihydrogen orthophosphate in distilled water
and volume adjusted to produce 1000 ml.
Sodium hydroxide 0.2 M:
8.0 grams of NaOH was dissolved in distilled water and volume adjusted to produce
1000 ml63.
Table no.4.1: Preparation of 6.6 pH phosphate buffer solution
pH Potassium hydrogen
phosphate solution
0.2M(ml)
NaOH 0.2M
Solution (ml)
Adjusted (ml) to
6.6 50 16.4 200
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b. Preparation of Standard Stock Solution:
Standard stock solution of doxycycline hyclate was prepared by dissolving accurately
weighed 100mg of doxycycline hyclate in small quantity of 6.6 pH phosphate buffer
in 100ml volumemetric flask. The volume was made up to 100ml by using 6.6 pH
buffer to obtaine the solution of 1000µg/ml.
c. Determination of Analytical Wavelength:
Scanning of Doxycycline Hyclate by UV Spectrophotometer:
From the standard stock solution 4ml was pipetted out into 100ml of volumemetric
flask. The volume was then made up to 100ml with 6.6 pH phosphate buffer. The
resulting solution containing 40µg/ml was scanned between 200-400nm and scan is
shown in Figure no.6.1.
Calibration Curve of Doxycycline Hyclate in 6.6 pH Phosphate Buffer:
From the standard stock solution of doxycycline hyclate (40µg/ml), Appropriate
liquates were taken in to different volumetric flask and volume made up to 10ml with
6.6 pH phosphate buffer, so as to get solution with drug concentration of 4 to 24
µg/ml. The absorbencies of the drug solution were measured at 274nm.These
procedure was performed six times to validate the calibration curve. The data are
given in Table no.6.1. The calibration curve constructed is showed in Figure no.6.2.
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4. PREPARATION OF INSERTS
Inserts were prepared by using antimicrobial agent Doxycycline hyclate and polymer
chitosan by solvent casting method.
a. Preparation of drug loaded chitosan inserts:
The general flow diagram for the preparation of chitosan inserts was given in figure
4.1. Chitosan (2% w/v) was soaked in acetic acid (1% v/v in water) for 24 hours to
get a clear solution. This dispersion was filtered through a muslin cloth to remove
undissolved portion of the polymer (chitin). Required amount of the drug was added
and vortexed for 1-2 hrs to dissolve the drug in chitosan solution. The viscous
dispersion was kept aside for complete expulsion of air bubbles. The films were
casted by pouring the drug-polymer dispersion into the center of leveled glass moulds
and allowed to dry at room temperature (30°C) for 24 hours. After drying, films were
cut into inserts of required size (7 × 2 mm). Inserts containing zero percent (placebo),
10%, 20% and 30% w/w of the drugs to the weight of polymer were prepared These
were wrapped in aluminum foil and stored in desiccators until further use 56.
b. Preparation of bi-layer inserts:
15 ml 2% chitosan cast solution without drug was poured into mould and dry at room
temperature to form the first layer of bi-layer membrane. 20 ml chitosan cast solution
with 30% drug was cast on the first layer and it was dried to room temperature. Then
the dried inserts were kept in desiccators for further study56.
c. Preparation of tri-layer membrane:
15 ml of 2% chitosan cast solution without drug was cast into mould and then dried to
room temperature to form the down layer of the tri-layer. 20 ml chitosan cast solution
with 30% drug was cast on the down layer after it was dry to form the middle layer of
the tri-layer. And then 15 ml of 2% cast solution without drug was cast onto the
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previous membrane also after it had been dry again to form the upper layer of the tri-
layer. Then dried inserts were kept in desiccators for further use.
Table No. 4.2: Composition of different periodontal inserts
Inserts Inserts code % of drug loaded
Plain Inert CP 0
Single layer DSL-10 10
Single layer DSL-20 20
Single layer DSL-30 30
Bilayer insert DBL-30 30
Trilayer insert DTL-30 30
CP = Chitosan polymer, DSL-10, 20, 30= Doxycycline single layer with 10%, 20% and 30%, DBL-30
=Doxycycline bilayer with 30% and DTL-30= Doxycycline trilayer with 30%.
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24
Chitosan + 1% v/v acetic acid
Kept aside for
4 hours
Vortexed for
15 minutes
Viscous solution of chitosan
Filtered
Clear solution of chitosan
Drug Vortexed for
15 minutes
Viscous solution of drug
in polymer (chitosan)
Air bubbles were
removed, by keeping
aside
Pouring in the
die
Drying at room
temperature
(30 ± 2° C)
Removed from the die and
stored in the desiccators
Figure No. 4.1: Protocol for the Preparation of Drug Loaded Chitosan Inserts
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5. CHARACTERIZATION OF THE POLYMERIC INSERTS
All the prepared periodontal inserts were evaluated for various parameters like
thickness, weight variation, folding endurance, tensile strength, drug content, in vitro
release, swelling index, in-vitro anti microbial activity and stability studies.
a) Thickness Measurement:
The thickness of the polymer inserts (2x7 cm) was measured by using a digital screw
gauge (Mitutoyo) at different areas of the inserts and the average was calculated53.
b) Weight Variation:
The weight variation test was carried out by weighing 6 inserts cut from different
places of same formulation and their individual weights were determined by using the
digital balance. The mean valve was calculated. The standard deviations of weight
variation were computed from the mean value53.
c) Folding Endurance Studies:
Folding endurance of the inserts was determined by repeatedly folding the insert at
the same place till it broke or folded. The number of times, the insert could be folded
at the same place, without breaking, gave the value of folding endurance53.
d) Tensile Strength Measurement:
Tensile strength of the inserts was determined by Universal strength testing machine.
It consists of two load cell grips, the lower one is fixed and upper one is movable. The
test inserts of specific size (2 × 2 cm) was fixed between these cell grips and force
was gradually applied till the film breaks. The tensile strength of the inserts was taken
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directly from the dial reading in kilograms Measurements were run in triplicate for
each film53.
Figure No. 4.2: Digital Tensile Strength Measurement Instrument.
e) Estimation of Drug Content:
The drug loaded chitosan insert of known weight (7 × 2 mm) were dissolved in small
volume of 1% (v/v) acetic acid and drug solution was suitably diluted with 6.6 pH
phosphate buffer and the absorbance was measured at  274nm53.
f) Percentage Moisture Absorption:
The percentage moisture absorption test was carried out to check physical stability or
integrity of the inserts. Periodontal inserts of known size were weighed and placed in
a dissector containing 100ml of saturated solution of aluminum chloride and 79.5%
humidity was maintained. After three days the inserts were taken out and reweighed.
The percentage moisture absorption was calculated using the formula.
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% Moisture absorbance = Final weight – Initial weight      x 100
Initial weight
g) Percentage Moisture Loss:
The percentage moisture loss test was carried out to check physical stability or
integrity of the inserts. Periodontal inserts of known size were weighed and placed
in a dissector containing 100ml of saturated Calcium chloride and 79.5% humidity
was maintained. After three days the inserts were taken out and reweighed. The
percentage moisture loss was calculated using the formula.
% Moisture Loss = Initial weight – Final weight      x 100
Final weight
h) Determination of Water Uptake and Swelling Behavior:
Water uptake was determined gravimetrically. Drug loaded inserts were placed on
a filter paper. The lower side of filter paper was immersed in a beaker containing
6.6 pH phosphate buffer, and incubated at 30 0C. Weight of each inserts was
determined with digital weight balance at predetermined time points. The size
changes of the inserts due to swelling investigated macroscopically.
i) In-Vitro Antibacterial activity:
In-vitro antibacterial activity was performed on all formulation by placing the
insert (2x7) on agar plates seeded with oral bacteria steptococuss mutans. After 48
hrs of incubation at 37 0C, the inserts were transformed to freshly seeded agar
plates and incubated for additional 48 hrs. This procedure was repeated until no
inhibition of bacterial growth was detected on agar plate. The growth inhibition
zone on the agar plate was measured.
57
j) In-vitro Release Studies:
Since the pH of the gingival fluid lies between 6.5 – 6.8, phosphate buffer pH 6.6 was
used as simulated gingival fluid for the dissolution studies and the inserts remains
immobile in the periodontal pocket, a static dissolution model was adopted.
A static dissolution method reported in the literature was adopted in this thesis. Sets
of 3 inserts of known weight and dimension (7 × 2 mm) were placed separately into
small test tubes containing 1.0 ml phosphate buffer, pH 6.6. The tubes were sealed
and kept at 37°C ±1 for 24 hours. The buffer was then drained off and replaced with a
fresh 1.0 ml phosphate buffer pH 6.6. The concentration of drug in the buffer was
measured at 274nm .The procedure was continued for consecutive days53.
6. DEPENDENT-MODEL METHOD (KINETIC MODELING):
The results obtaining in vitro release studies were plotted in different models of data
treatment as follows:
ZERO ORDER KINETIC
It describes the system in which the drug release rate is independent of its
concentration.
Qt = Qo + Ko t
Where,
Qt= Amount of drug dissolved in time t
Qo = Initial amount of drug in the solution, which is often zero and
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Ko = zero order release constant.
If the zero order drug release kinetic is obeyed, then a plot of Qt versus t will give a
straight line with a slope of Ko and an intercept at zero.
FIRST ORDER KINETIC:
It describes the drug release from the systems in which the release rate is
concentration dependent.
Mt / M∞ = ktn
Log [Mt / M∞] =   log k + n
Where,
Qt = amount of drug released in time t.
Qo = initial amount of drug in the solution
k = first order release constant
If the first order drug release kinetic is obeyed, then a plot of log (Qo- Qt) versus t
will be straight line with a slope of kt / 2.303 and an intercept at t=0 of log Qo.
HIGUCHI MODEL:
It describes the fraction of drug release from a matrix is proportional to square root of
time.
Log Qt = log Qo + kt / 2.303
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Where,
Mt and M∞ are cumulative amounts of drug release at time t and infinite time, and
kH = Higuchi dissolution constant reflection formulation characteristics.
If the Higuchi model of drug release (i.e. Fickian diffusion) is obeyed, then a plot of
Mt / M∞ versus t1/2 will be straight line with slope of kH.
KORSMEYER-PEPPAS MODEL (POWER LAW):
The power law describes the drug release from the polymeric system in which release
deviates from Fickian diffusion, as expressed in following equation.
Mt / M∞= kHt1/2
Where,
Mt and M∞ are cumulative amounts of drug release at time t and infinite time
(i.e. fraction of drug release at time t),
k = constant incorporating structural and geometrical characteristics of CR d
device,
n = diffusional release exponent indicative of the mechanism of drug release
for drug dissolution.
• To characterize the release mechanism, the dissolution data {Mt / M∞ <0.6} are
evaluated.
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• A plot of log {Mt / M∞} versus log t will be linear with slope of n and
intercept gives the value of log k.
• Antilog of log k gives the value of k.
• Peepas used the n value in order to characterize different release mechanisms as
shown in the table below,
Table No.4.3: Release Mechanism of Peppas
‘n’ MECHANISM
0.5 Fickian diffusion
0.5 < n <1 Non- fickian diffusion
1 Class II transport
Stability Studies:
The stability of the drug loaded polymer inserts were studied at different temperatures
using the reported procedure. The 3 inserts of size (7 × 2 mm) were weighed. The
strips were wrapped in aluminum foil and placed in petridishes. These container was
stored at ambient humid conditions, at room temperature (27 ± 2°C), oven
temperature (40 ± 2°C) and in refrigerator (5 - 8°C) for a period of 3 months. The
samples were analyzed for physical changes such as color and texture.
The drug content was estimated at an interval of 1 month using the procedures
reported earlier in this thesis53.
The results obtained from these methods and the discussion of the obtained results is
given in the following chapter “Results and Discussion”.
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8.RESULT AND DISCUSSION
Periodontal inserts were prepared by solvent casting method and inserts were
characterized for various parameters like thickness, weight variation, swelling index,
moisture absorption, folding endurance, tensile strength, percentage moisture loss,
drug content, stability study and in-vitro release studies. Table no.4.2 shows
composition of various formulations of periodontal inserts with aimed at providing
local long term release of Doxycycline (DCL).
1. PREFORMULATION STUDIES
The following preformulation studies were performed for drugs and polymer.
Determination of Melting Point:
Melting point was determined and it was found to be 2020- 2030C ±20C (N =3). This
value is very close to that of literature citation. Thus, indicating purity of the drug.
2. EXPERIMENTAL METHODS
a) Analytical Methods
Determination of λ max:
Absorption spectrum of doxycycline hyclate was obtained using phosphate
buffer pH 6.6 by scanning the sample in UV spectrophotometer in the range of 200-
400 nm. The absorption maxima were found to be at 274 nm and the spectra is shown
in the figure no.6.1.
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Figure No.6.1: Analytical Wavelength of Doxycycline Hyclate.
Calibration Curve of Doxycycline:
Table no.6.1 shows the absorbance reading of DCL. Standard solutions containing
4- 24 µg/ml in phosphate buffer pH 6.6. Figure no. 6.2 shows standard calibration
curve for DCL with the correlation coefficient of 0.997. The drug content uniformity
and in vitro drug release study are based on this calibration curve. The absorbance
was measured at λ max of 274 nm.
Table No. 6.1.: Calibration Data of Doxycycline hyclate in 6.6 pH Phosphate
Buffer.
SL.NO. CONCENTRATION
(µg/ml)
ABSORBANCE*
AM ±SD
1 4 0.157 ± 0.002
2 8 0.264 ± 0.005
3 12 0.413 ± 0.006
4 16 0.523 ± 0.001
5 20 0.684± 0.028
6 24 0.778 ± 0.007
Each value is an average of six replications* R2=0.997
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Figure No.6.2: Calibration Curve of Doxycycline in pH 6.6 Phosphate Buffer.
3.    DRUG EXCIPIENT COMPATIBILITY STUDIES
• Fourier Transform Infrared Spectroscopy (FT-IR) studies:
The preformulation studies between the drug and formulation component under
the experimental conditions were done by using IR spectrum and was recorded on
shimadzu FT-IR by preparing KBr disc. The entire characteristics peak obtained in the
spectra’s of the formulation correlate with peaks of drug spectrum. This indicates that
the drug is compatible with all the formulation components. The spectra of all
formulations were shown Figure no. from 6.3-6.5.
The results of IR spectral analysis showed the following major peaks for DCL,
chitosan and their formulation components are tabulated in the table no.6.2.
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Figure No.6.3: Fourier Transform Infrared Spectroscopy (FT-IR) of Doxycycline.
Figure No. 6.4: Fourier Transform Infrared Spectroscopy (FT-IR) Of Chitosan.
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Figure No.6.5: Fourier Transform Infrared Spectroscopy (FT-IR) of formulation.
Fourier Transform Infrared Spectroscopy:-
The peaks of formulation were compared with the peaks of the drug and we found the
maximum similarities. Finally we conclude that the drug retains its originality even
after formulation, so the drug may not get disturbed in the formulation.
Table No.6.2: Data of the FT-IR Spectra of Pure Doxycycline(DCL) and Polymer
Chitosan Peaks of Functional Group (Cm-1).
FORM
ULATI
ON
C=O
Stretch
i-ng
cm-1
Ar-
CH
Stretc
hi-ng
cm-1
-OH
stretch-
ing
cm-1
N-H
bendi-
ng
cm-1
-OH
bendin-
g cm-1
C-N
Stretchi-
ng cm-1
C-C-C O
Stretchi-
ng cm-1
DCL 1615.65 2900 3330 1570 1460.73 1243.79 1175.32
DCL+
Chito-
san
1615.6
4 2967 3330.33 1578.06 1460.37 1243.58 1175.37
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• Differential Scanning Calorimetry:
DSC is useful in the investigation of solid state interactions. Thermograms are
generated for pure drug and physical mixtures of drug along with other excipients. In
the absence of any interaction, the thermogram of mixtures show endothermic peak
corresponding to that of  pure  drug. In the event that interaction occurs, this is
indicated in the thermogram of a mixture by  the shift in the value of melting
endotherm of the pure drug.
The DSC thermogram of pure DCL and its mixture with different excipients
are shown in figure. Pure DCL showed a sharp endotherm at 219.78C corresponding
to its melting point/transition temperature. There was no appreciable change in
endotherm peaks of formulation compared to pure drug. This observation further
supports the IR spectroscopy results, which indicated the absence of any interaction
between drug and additives used in the preparation.
Figure No.6.6: Differential Scanning Calorimetric (DSC) Thermogram of
Doxycycline Hyclate Drug.
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Figure No.6.7: Differential Scanning Calorimetric (DSC) Thermogram of
Chitosan Polymer.
Figure No.6.8: Differential Scanning Calorimetric (DSC) Thermogram of
Formulation.
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4. Preparation of Drug Loaded Chitosan Inserts:
The optimum concentration of chitosan used for the preparation of inserts was found to
be 2% w/w, because at this concentration the  inserts were flexible and easily
removable from die, at higher conc. of polymer, the polymer dispersion was highly
viscous and difficult to filter using muslin cloth, inserts were brittle and difficult to
remove from die.
The amount of drug added to polymer solution changes the inserts characteristics an
optimum conc. of drug to be loaded was found to be less than 30% w/w to polymer, at
higher drug conc. (i.e. >30%) the inserts were stiff and brittle. Plasticizer was not used
because inserts obtained were flexible with plain chitosan. There was no visible sign of
crystallization.
5. Evaluation of Physical Parameters of DCL Loaded Chitosan Inserts:
a) Physical appearance:
Both drug and polymer combination used for formulation of periodontal inserts
showed good film properties and reproducibility. The fabricated inserts were thin,
flexible, elastic, smooth and non transparent.
Photography of doxycycline hyclate was shown in the figure no.6.6.
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Figure No.6.8: Photograph Showing Doxycycline Hyclate Periodontal Inserts.
1) Plain Chitosan Insert 2) Single Layer With 10% of DCL
3) Single Layer With 20% of DCL 4) Single Layer With 30% of DCL
5) Bilayer Layer With 30% of DCL 6) Trilayer Layer With 30% of DCL
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b) Thickness Measurement:
Thickness of each insert was measured at six different points and average thickness
with standard deviation was calculated. The thickness of the various inserts as given
in the table no.6.3. The data of inserts thickness indicates that there was no much
difference in the thickness within the formulation. The thickness of the inserts was
increased as increased in the drug concentration and more thickness was obtained in
bilayer and trilayer respectively.
c) Weight variation test:
Drug loaded inserts (2X7) were test for uniformity of weight, the results of weight
uniformity are given in the table no.6.3 with less standard deviation values which
indicates that  the inserts were uniform in  weight. The data of weight uniformity
indicates that as the concentration of the drug increases there is an increase in the
weight of the insert. This is an agreement with uniformity of thickness of the film as
shown in the table no.6.3.
d) Folding endurance:
Table no.6.3. Shows the value of folding endurance. There replication of each test was
carried out. It was found that folding endurance of the inserts was decreased by
increase  in the drug concentration. Bilayer and trilayer inserts exhibits minimum
folding endurance as compared to the other inserts. It is evident from the literature that
the films having folding endurance having more than 100-150 is considered as
optimum. In the present study the folding endurance was reduced in all inserts upon
the increase in concentration of drug and also formulating into bilayer and trilayer
inserts. However, the folding endurance of the bilayer and trilayer inserts containing
30% drug was also more than 150. Therefore the inserts of the study were having very
good folding endurance and can be considered as optimum.
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Table No. 6.3: Data of Physical Measurement values of Doxycycline Inserts.
Insert
Code
Thickness
( mm)AM ± SD
Folding
Endurance
Weight
Uniformity
(mg)
CP 0.103±0.0157 340±2.581989 0.8±0.208167
DSL-10% 0.124 ±0.049 280±14.719 1.0± 0.208
DSL-20% 0.171 ±0.278 260.75±13.50 1.5 ±0.346
DSL-30% 0.197 ±0.024 201.75±19.431 2.2 ±0.057
DBL-30% 0.360 ±0.010 187±9.128 2.9 ±0.30
DTL-30% 0.456±0.0030 155.25±9.844 3.9 ±0.888
e) Percentage Moisture Loss:
This test is of great significance as variation in moisture content causes a significant
variation in mechanical properties of the inserts especially when inserts comprises of
hygroscopic components. Moisture loss studies were conducted on various
formulations and reported in the Table no.6.3. It was observed  that formulations
containing maximum amount of drug showed maximum amount of moisture loss
because of more concentration of drug which undergoing moisture loss in dry
condition.
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Table No.6.4: Data for Percentage Moisture Loss of Doxycycline Inserts.
INSERT CODE MOISTURE LOSS
(%) AM ± SD
CP 24.155±7.35
DSL-10% 24.77 ±12.365
DSL-20% 25.318±12.744
DSL-30% 25.37± 6.4593
DBL-30% 31.498±12.879
DTL-30% 40.43±11.737
Figure No.6.9: Graph for Percentage Moisture Loss of Doxycycline Inserts.
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f) Percentage Moisture Absorption:
This test is of great significance as variation in moisture content causes a significant
variation in mechanical properties of the inserts especially when inserts comprises of
hygroscopic components. The capacity of the inserts to take up water is an important
intrinsic parameter of the polymeric system in consideration to the release of drug.
The data are given in the Table no. 6.4.
Table No.6.5: Data for Percentage Moisture Absorption of Doxycycline Inserts.
INSERT CODE MOISTURE ADSORPTION
(%) AM ± SD
CP 28.35± 16.02
DSL-10% 28.43±5.533
DSL-20% 32.048±20.18
DSL-30% 32.526±5.501
DBL-30% 38.393±11.366
DTL-30% 40.97 ±13.625
Figure No.6.10: Graph for Percentage Moisture Absorption of Doxycycline
Inserts.
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g) Water Uptake and Swelling Behavior:
Water uptake and swelling behavior studies were conducted on formulated inserts.
Water uptake was found to be maximum with bilayer and trilayer inserts this may be
due to the presences of more concentration of chitosan. The results are showed in the
table no. After complete hydration, moderate swelling of the polymer were observed
and there is a slight increase in the diameter of inserts.
Table No.6.6: Data for Swelling Index of Doxycycline Inserts.
INSERT CODE WATER UPTAKE AND SWELLING
BEHAVIOUR
INITIAL WEIGHT
(mg) (0hr)
FINAL WEIGHT (mg)
(2hrs)
CP 4.3 4.6
DSL-10 4.7 6.3
DSL-20 4.1 4.8
DSL-30 3.5 5.8
DBL-30 4.5 4.7
DTL-30 5.1 7.4
h) Tensile Strength :
The tensile strength was determined using universal testing tensile machine for both
drug loaded and unloaded inserts. The result are given in the table no.6.7. The tensile
strength of drug loaded inserts was higher than dummy inserts. This is because of
dissolved drug strengthen the bounding of polymer chain.
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Table No.6.7: Data for Tensile Strength of Doxycycline Insert.
INSERTS
CODE
TENSILE STRENGTH
(Kg/sq.mm.)
AM ± SD
CP 1.45± 0.054
DSL-10 2.140±0.110
DSL-20 2.318±0.185
DSL-30 2.810±0.060
DBL-30 3.170±0.102
DTL-30 4.533±0.200
*Each value was an average of three determinations.
Figure No.6.11: Graph for Tensile Strength of Doxycycline Inserts.
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i) Drug Content Uniformity:
The drug content uniformity test is commonly employed for unit dose form in order to
make sure about the uniform dispersion of drug in the inserts. The drugs content value
of prepared inserts contains doxycycline hyclate were reported in the table no.6.8. The
drug loading varied from 80-98 % depending on initial drug concentration and type of
formulation.
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Table No.6.8: Data of Drug Content Uniformity of Doxycycline Insert.
Inserts Code Drug Content* (µg) Theoretical
Drug Loading
(µg)
% Drug
Loading
CS ---- ---- ---
DSL-10 107.810± 0.054 109.300 98.63
DSL-20 216.562± 0.089 218.250 99.00
DSL-30 274.062± 0.071 328.125 83.523
DBL-30 273.135± 0.064 328.125 83.241
DTL-30 272.279± 0.022 328.125 82.980
j) In-vitro Drug Release:
Since the pH of gingival fluid is between 6.5 to 6.8, phosphate 6.6 pH was used on
stimulated gingival fluid for dissolution studies. Since, the inserts remain immobile in
the periodontal pocket as static dissolution model was adopted in this work.
Release of DCL from Chitosan Inserts:
The release data of doxycycline hyclate are given in the table no.6.9, 6.10, and 6.11.
The release studies were conducted for 8 days for single layer which containing
different concentration of drug. The release time profiles from these inserts were
shown in figures. From the results it was found that there was rapid initial release of
drug on day 1 and there was a marked reduction in release from day 3 onwards and
the release was controlled and extended up to 8 days.
The cumulative percentage drug release was 96.83%, 91.009 % and 92.210 % from
inserts containing 10%, 20% and 30% of drug from single layer respectively.
A Persuval of figure no.6.12. indicated that initial rapid release must be due to burst
release effect. Burst release is due to elution of drug from the outer surface and cut
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edges of the matrix. Once the burst was completed (2days), drug was more sustained
up to 8 days. Based on the results single layer inserts of 30% drug concentration was
chosen for bilayer and trilayer studies respectively. These studies became essential in
order to control the burst effect and release for more number of days.
Release of Doxycycline Hyclate from Bilayer and Trilayer:
The release data of bilayer and trilayer 30% DCL are given in the table no.6.12 and
6.13. The release time profile from bilayer and trilayer are showed in figure no.6.12.
The bilayer and trilayer inserts showed a decreased initial burst release by more than
40%. The drug release was controlled and extended up to 13 days in case of bilayer
where as 17 days in case of trilayer respectively.
The cumulative % release of drug from single layer insert was about 90-95% on the
8th day. However the release of drug from bilayer and trilayer insert was about 90%
on 13th and 17th day. Hence, it might be informed that developing bilayer and trilayer
helped in sustaining the release for more number of days for local long term treatment
for periodontitis.
Table No.6.9: Static Dissolution-Time Profile for Chitosan Inserts Containing
Doxycyline-10%.
Time
(days)
Absor
bance*
Dilution
factor
Conc. of
drug
released (µg)
AM ± SD
Cumulative
release (µg)
% conc.
of drug
released
‘a’
% conc.
of drug
unreleas
ed
01 0.405 5 61.562 61.562 57.1023 42.897
02 0.135 5 19.375 80.937 75.073 24.927
03 0.074 5 9.843 90.780 84.136 15.864
04 0.052 5 6.406 97.186 90.1456 94.059
05 0.025 5 2.187 99.373 92.1741 7.8257
06 0.024 5 2.031 101.404 94.0580 5.942
07 0.027 5 2.343 103.747 96.231 3.769
08 0.018 3 0.656 104.403 96.839 3.161
• Each value is an average of three replication, Medium - Phosphate buffer 6.6 pH.
• Static dissolution conditions are: Temperature=37° C
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Table No.6.10: Static Dissolution-Time Profile for Chitosan Inserts Containing
Doxycyline-20%.
Time
(days)
Absorb
ance*
Dilution
factor
Conc. of
drug
released
(µg)
AM ± SD
Cumulative
release (µg)
% conc.
of drug
released
‘a’
% conc. of
drug
unreleased
01 0.350 10 105.937 105.937 48.917 51.083
02 0.417 5 63.437 169.374 78.2103 21.789
03 0.103 5 14.375 183.749 84.848 15.152
04 0.042 5 4.843 188.592 87.0845 12.916
05 0.031 5 3.125 191.717 88.527 11.473
06 0.028 5 2.656 194.373 89.7539 10.247
07 0.030 3 1.781 196.154 90.576 9.424
08 0.021 3 0.937 197.091 91.009 8.991
• Each value is an average of three replication*
• Static dissolution conditions are: Temperature=37° C
• Medium = Phosphate buffer, pH 6.6 (l ml).
Table No.6.11: Static Dissolution-Time Profile for Chitosan Inserts Containing
Doxycyline-30%.
Time
(days)
Absor
bance
Dilution
factor
Conc. of
drug
released (µg)
AM ± SD
Cumulative
release (µg)
% conc.
of drug
released
‘a’
% conc. of
drug
unreleased
01 0.499 10 152.50 152.50 55.644 44.356
02 0.453 5 69.062 221.562 80.843 19.157
03 0.125 5 17.812 239.374 87.343 12.657
04 0.058 5 7.343 246.717 90.022 9.978
05 0.025 5 2.187 248.904 90.820 9.180
06 0.022 5 1.718 250.622 91.447 8.553
07 0.019 5 1.25 251.872 91.903 8.097
08 0.020 3 0.843 252.715 92.210 7.790
• Each value is an average of three replication*
• Static dissolution conditions are: Temperature=37° C
• Medium = Phosphate buffer, pH 6.6 (l ml).
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Table No.6.12: Static Dissolution-Time Profile for Chitosan Bilayer Inserts
Containing Doxycyline-30%.
Time
(days)
Absorb
ance*
Dilution
factor
Conc. of
drug
released
(µg)
AM ± SD
Cumulative
release (µg)
% conc.
of drug
released
‘a’
% conc. of
drug
unrelease
d
01 0.469 10 143.125 143.125 52.400 47.600
02 0.365 5 55.312 198.437 72.651 27.349
03 0.166 5 24.218 222.655 81.518 18.482
04 0.068 5 8.906 231.561 84.778 15.222
05 0.039 5 4.375 235.936 86.380 13.620
06 0.030 5 2.968 238.904 87.467 12.533
07 0.025 5 2.187 241.091 88.268 11.732
08 0.033 3 2.062 243.153 89.023 10.977
09 0.030 3 1.781 244.934 89.675 10.325
10 0.029 3 1.6875 246.621 90.292 9.708
11 0.023 3 1.125 247.746 90.704 9.296
12 0.020 3 0.843 248.589 91.013 8.987
13 0.018 3 0.656 249.245 91.253 8.747
• Each value is an average of three replication*
• Static dissolution conditions are: Temperature = 37° C
• Medium = Phosphate buffer, pH 6.6 (1 ml).
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Table No.6.13: Static Dissolution-Time Profile for Chitosan Tri Layer Inserts
Containing Doxycyline-30%.
Time
(days)
Absorb
ance*
Dilution
factor
Conc. of drug
released (µg)
AM ± SD
Cumulative
release (µg)
% conc.
of drug
released
‘a’
% conc.
of drug
unreleas
ed
01 0.363 10 110.00 110.00 40.399 59.601
02 0.375 5 56.875 166.875 61.288 38.717
03 0.165 5 24.062 190.937 70.125 29.874
04 0.130 5 18.593 209.53 76.954 23.045
05 0.069 5 9.0625 218.592 80.282 19.717
06 0.043 5 5.000 223.592 82.118 17.881
07 0.035 5 3.750 227.342 83.495 16.504
08 0.027 5 2.500 229.842 84.414 15.585
09 0.025 5 2.187 232.029 85.217 14.783
10 0.023 5 1.875 233.904 85.906 14.093
11 0.027 3 1.500 235.404 86.456 13.543
12 0.025 3 1.312 236.716 86.938 13.061
13 0.023 3 1.125 237.841 87.351 12.648
14 0.021 3 0.937 238.778 87.696 12.303
15 0.019 3 0.750 239.483 87.955 12.044
16 0.017 3 0.562 240.045 87.996 12.003
17 0.015 3 0.375 240.420 88.299 11.700
• Each value is an average of three replication*
• Static dissolution conditions are: Temperature = 37° C,
• Medium = Phosphate buffer, pH 6.6 (1 ml).
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Figure No.6.12: Cumulative Percentage Release of Doxycycline Hyclate from
Chitosan Inserts.
6.     RELEASE KINETICS:
The release data of doxycycline hyclate was proposed to understand the linear
relationship. The data was proposed for reggration analysis.
Release Mechanism:
Since the drug loaded chitosan inserts were intact during static dissolution studies,
dissolution rate control release was ruled out. Hence data was fit according to higuchi
ficks modle.
A Persuval of figure indicated that linear relationship was observed from 3rd to 8th day
in case of single layer and 3rd to 13th day and 17th day in case of bilayer and trilarer
respectively. The apperances of straight line indicates the release of drug from
prepared inserts were diffusion rate control.
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DEPENDENT-MODEL METHOD (KINETIC MODELING)
The results obtaining in vitro release studies were plotted in different models of data
Treatment as follows:
 ZERO ORDER
 FIRST ORDER
 HIGUCHI EQUATION
 KORSEMEYER PEPPAS EQUATION
FIRST ORDER:-
Log of % Cumulative Drug Release VS. Time
Best Fit line for first order equation for chitosan inserts containing doxycycline.
Formulations are (DSL-10%, DSL-20%, DSL- 30%, DBL-30% and DTL-30%).
Figure No.6.13: First Order Equation for Chitosan Inserts Containing
Doxycycline hyclate
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HIGUCHI EQUATION:-
% Cumulative Drug Release Vs. Square Root of Time
Best Fit line for Higuchi equation for chitosan inserts containing doxycycline.
Formulations are (DSL-10%, DSL-20%, DSL- 30%, DBL-30% and DTL-30%)
Figure No.6.14: Higuchi Equation for Chitosan Inserts Containing Doxycycline
hyclate
KORSEMEYER PEPPAS EQUATION:-
Log of % Cumulative Drug Release Vs. Log Of Time
Best Fit line for Korsemeyer Peppas equation for chitosan inserts containing
doxycycline. Formulations are (DSL-10%, DSL-20%, DSL- 30%,DBL-30% and
DTL-30%) .
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Figure No.6.15: Korsemeyer Peppas Equation For Chitosan Inserts Containing
doxycycline hyclate.
The results obtaining by In-vitro release studies were plotted in different kinetic
models as follows.
Table No.6.14: Data of Kinetic modeling of Doxycycline Inserts.
INSERT
CODE
ZERO ORDER FIRST
ORDER
HUGUCHI
MATRIX
KORSEMEYER
PEPPAS
R² R² R² R² N
DSL-10 0.559 0.952 0.887 0.415 0.937
DSL-20 0.596 0.806 0.847 0.422 0785
DSL-30 0.559 0.766 0.823 0.402 0.789
DBL-30 0.479 0.743 0.738 0.388 0.811
DTL-30 0.513 0.750 0.764 0.421 0.822
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k) In-Vitro Antibacterial Activity:
Table no. 6.15. Shows more in-vitro antibacterial activity against S. mutans was found
on day1 with all single layer inserts. Whereas with bilayer and trilayer less activity
was observed on day 1. From the study it was conformed that bilayer and trilayer
inserts exhibited antibacterial activity for a long period in comparison to single layer.
This may be due to sustained release of drug from bilayer and trilayer inserts. The
zone of inhibition values of DCL shown in figure no.6.16.
Table No.6.15: In vitro antibacterial activity data of Doxycycline hyclate.
Days Diameter of inhibition of growth area of S.mutans (mm)
DSL-10 DSL-20 DsL-30 DBL-30 DTL-30
1 16 20 26 23 20
2 14 17 22 18 17
4 10 13 16 14 13
8 7 10 11 12 11
11
-
- - 10 9
14
-
- - 9 7
17
-
- - 7 5
Figure No.6.16: Zone of inhibition of Doxycycline Hyclate.
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L) Stability Study:
All the polymeric inserts were obsersved for physical change, color, appearance and
drug content. Stability data at different temperature and humidity condition revelaed
on physical appearances and uniformity in drug content. The drug remained intact and
stable  in the  polymer on storage for 3 months. The results obtained from these
methods and the discussion of the obtained results is given in the following tables.
Table No.6.16: Data for Physical appearance of Drug Stability Study.
TIME
IN
DAYS
DSL-10 DSL-20 DSL-30 DBL-30 DTL-30
0 No change
30 No change
60 No change
90 Yellow to brown
Table No.6.17: Stability Studies for Drug Content at various temperatures for
Chitosan Inserts Containing Doxycycline Hyclate.
Insert code Initial drug
conc. (µg)
30 Days 60 Days 90 Days
A.F A.F A.F
DSL10 107.810 107.800 107.783 107.700
DSL-20 216.562 216.560 216.534 216.487
DSL-30 274.062 274.058 274.022 273.987
DBL-30 273.135 273.130 273.102 273.029
DTL-30 272.279 273.274 273.250 273.147
Each value is an average of 3 determinations.
A.F = Packed in aluminum foil.
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The inserts were also observed for their appearance, texture and drug content
uniformity.   These properties did not change in all the inserts during the period of
study. Hence, prepared formulations have a good stability.
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9.SUMMMARY
Periodontitis is the disease, which is caused by specific microorganism in
periodontal pockets and led to an increased interest in and usage of antibacterial agent
in periodontal therapy.
The problems of administering drugs systemically, such as adverse reaction,
have focused attention on ways of applying the drug directly to its target site.
The use of drugs to treat plaque associated periodontal diseases is an attractive
prospect, since conventional treatment can be demanding on both patient and operator.
So there is much interest in developing alternative strategies.
Number of drug delivery system has been investigated for administration of
antibacterial / antimicrobial agents into periodontal pocket for local action in the
treatment of periodontitis.
Device placed into periodontal pocket can produce a local drug concentration
100 times higher than achievable systemically and importantly reduces the total patient
dose by over 400 fold.
For developing the local drug delivery system, as it was proved antimicrobial agent is
effective against wide range of oral pathogens.
Mucoadhasive dosage form utilizes the mechanism of bioadhesion and
produces an  intimate contact  with the biological  membrane.  Hence, chitosan was
selected as a biodegradable polymer for the development of drug delivery device
which stays for longer time at the site of action
The inserts of chitosan polymer (biodegradable) 2% w/v were prepared by
solvent casting method using 1% v/v acetic acid as a casting solvent. In the present
work chitosan inserts containing doxycycline hyclate were prepared in three different
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percentages (10%, 20% and 30%) to the weight of polymer .Bilayer and trilayer inserts
also were prepared for preventing initial burst release.
Microscopical feature revealed that the drug was dissolved in the polymer
matrix rather than dispersining. The average weight of single layer inserts range from
0.8 to 2.2 mg and average weight of bilayer and trilayer ranges from 2.9 to 3.9 mg. The
thickness of the insets ranges from 0.103±0.015 mm to 0.456±0.0030 mm. There was
no significant difference in the thickness among the different inserts since the drug
was dissolved in the polymer matrix. The tensile strength of the inserts range from
1.45 ± 0.054 kg to 4.533 ± 0.200 kg. Tensile strength is minimum for plain inserts and
maximum for inserts containing 30% drug. The data obtained revealed that
incorporation of drug increases the physical strength of the inserts, however this may
not cause any problem during their clinical application. The folding endurance studies
showed that plain inserts exhibited maximum folding endurance followed by drug
loaded inserts respectively.
In vitro dissolution rate studies were carried out by static dissolution method
for inserts for a period of 8, 13 and 17 days respectively. This showed a burst release
initially followed by a progressive fall in the release of the drug. The inserts DSL-10,
DSL-20 and DSL- 30 showed 96.839%, 91.009 % and 92.210% respectively at the
end of 8 days. The bilayer insert (DBL-30) showed 91.253% at the end of 13. The
trilayer insert (DTL-30) showed 88.299 % respectively at the end of 17days of static
dissolution period. Initial burst effect was reduced once the chitosan strips were
formulated in multilayer form and also release of drug was extended and controlled
up to 17 days. The plots of the cumulative amount of drug release per unit surface
area against sq. root of time, confirms to Higuchi’s diffusion model i.e., the release
kinetics of doxycycline from chitosan strips followed first order. The initial burst
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release is essential to achieve high concentration of drug in gingival sulcus. This is a
primary objective of the periodontal therapy.
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10.CONCLUSIONS
From the obtained results, it can be concluded that
 Novel multilayer inserts of doxycycline hyclate can be formulated by solvent
casting method technique.
 Evaluation parameters like thickness, tensile strength and folding endurance
indicates that inserts were mechanically stable in all the inserts formulations.
 Percentage weight variation and drug content uniformity found to be uniform in all
the formulations.
 The FT-IR and DSC spectra revealed that, there was no interaction between
polymer and drug. Hence, Polymer used was compatible with the drug.
 In-vitro drug release showed an abrupt release in the first day in single layer
whereas this initial burst release was controlled by formulating in to bilayer and
trilayer which was controlled the release uniformity in a specified period of time.
 In-vitro antibacterial activity showed good correlation with respective in-vitro
drug release. Release kinetics from all the inserts follows diffusion rate controlled
mechanism.
 All the inserts were found to be stable over the storage period of 90 days and
condition tested.
 From this study it can be concluded that bilayer and trilayer were developed which
can be delivered drug up to 13 and 17 days respectively.
 Future scope:-
 Addressing the final multilayer formulation needs considerable amount of study.
 In-vivo evaluation study of multilayer inserts of DCL and establishment of in-vitro
and in-vivo correlation.
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